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Eukaryotic gene expression is an integral network encompassing chromatin packaging, 
transcription, capping, polyadenylation, splicing, mRNA nuclear export, and translation. Pre-
mRNA splicing removes non-coding RNA sequences, generates proteomic diversity, and even 
affects other gene expression processes. Hence, dysregulated splicing has emerged as the origin 
of various diseases including cancer, representing an attractive therapeutic target. FR901464 is a 
natural bacterial metabolite that arrests tumor growth by interfering with the spliceosomal SF3b 
subcomplex. Meayamycin B, an FR901464 analogue synthesized by the Koide group, exhibited 
picomolar anti-proliferative activity in a broad spectrum of tumor cell lines. 
The first goal of this thesis project was to further characterize the biological activity of 
meayamycin B and identify downstream effectors, thereby discovering novel combination 
therapeutics for cancer. To that end, we first optimized a cell-based reporter system for splicing 
inhibition, which was subsequently used for a comprehensive comparison of meayamycin B with 
recently reported splicing modulators, including spliceostatin A, herboxidiene, and meayamycin. 
This study provides a handy guide in terms of the splicing inhibitory activity of these widely 
utilized compounds in both basic and translational research. 
To identify downstream effectors and their therapeutic applications, we focused on 
examining the B-cell lymphoma 2 (Bcl-2) family members that control the mitochondria-
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mediated cell death pathway –– apoptosis. This effort led us to myeloid cell leukemia sequence-1 
(Mcl-1), a Bcl-2 family member that is recurrently correlated with drug resistance and tumor 
refractory. Meayamycin B reversed the dominant splicing isoform from Mcl-1L to Mcl-1S, 
resulting in a proapoptotic cellular environment. Taking advantage of this effect, we combined 
meayamycin B with Bcl-xL inhibitor ABT-737 to trigger apoptosis in cancer cell lines that were 
otherwise resistant to either single agent. This potent combination was characterized in vitro in 
non-small-cell lung carcinoma (NSCLC) and head and neck squamous cell carcinoma (HNSCC) 
models. 
The second part of this thesis project was devoted to the biological characterization of a 
fungal metabolite TMC-205 and its stable analogs. These indole derivatives are both activators 
of Simian virus 40 (SV40) promoter and inhibitors of firefly luciferase, representing a new 
generation of anticancer agents with a multifactorial mode of action. 
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1.0  BACKGROUND 
1.1 PRE-MRNA SPLICING AND CANCER 
1.1.1 Spliceosome-mediated splicing process 
Eukaryotic genes undergo a multi-step processing prior to forming messenger RNAs (mRNAs) 
that are subsequently exported into cytoplasm for translation.1 One pivotal step is precursor 
mRNA (pre-mRNA) splicing, in which non-coding sequences (introns) are removed and protein-
coding sequences (exons) are joined to produce the mRNAs. In eukaryotes, splicing of protein-
coding gene transcripts is mostly carried out by the spliceosome, a macromolecular machinery 
composed of five small nuclear ribonucleoproteins (snRNPs) (the U1, U2, U4, U5 and U6) and 
more than 200 polypeptides.2 Self-splicing introns exist in rRNA, tRNA, mRNA of organelles 
(chloroplasts and mitochondria) in fungi plants and protists, and in bacterial mRNA.3  
The excision of an intron commences with the intricately regulated assembling of 
snRNPs onto pre-mRNAs to form an active spliceosome (Figure 1-1).4 This spliceosome is 
directed by special sequences at the intron/exon junctions called splice sites.5 Four consensus 
sequences at the splice sites define the exon-intron boundaries and direct the assembly of 
snRNPs. These sequences encompass GU/C at the intronic 5’ splice site that marks the 
exon/intron junction and three conserved sequence elements at the 3’ splice site region: the 
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branchpoint with the consensus adenine, the polypyrimidine tract, and the conserved AG at the 
3’ end of the intron.6  
To initiate the assembly of the spliceosome, U1 snRNP interacts with the 5’ end of the 
intron through RNA-RNA base-paring.7 Various serine/arginine-rich (SR) proteins assist in the 
recognition process. For 3’ splice site recognition, splicing factor-1 (SF-1) recognizes the 
branchpoint, and the 65 kDa and 35 kDa subunits of the U2 snRNP auxiliary factor (U2AF) bind 
to the polypyrimidine tract and 3’ AG, respectively.8-9 These interactions give rise to the 
spliceosomal complex E. U2 snRNP is also involved in complex E, but is only loosely attached, 
without direct interaction with pre-mRNA. Subsequently, U2 snRNP becomes stably bound to 
pre-mRNA at the expense of an ATP, completing the transition from complex E to complex A. 
Next, extensive ATP-dependent conformational changes within complex A facilitate the 
incorporation of U4-U5-U6 tri-snRNP to form the spliceosomal complex B.10-12 The U1 and U4 
snRNPs are then released,13 leaving behind the activated form of spliceosomal complex B* after 
further dynamic conformation changes, which performs the first step of splicing catalysis. 
Subsequently, complex C is formed and catalyzes the second transesterification reaction.14 
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Figure 1-1 Spliceosome assembly and activation along pre-mRNA 
 
 
 
 
 
 
 4 
In splicing catalysis, which comprises two sequential transesterification reactions, 
spliceosomal complex C brings crucial sequences in close proximity (Figure 1-2). During the 
first transesterification, the 2’ hydroxyl group of the adenine residue at the branchpoint sequence 
attacks the 5’ end of the intron as a nucleophile, forming a branched intermediate called an intron 
lariat. During the second transesterification, the 3’ hydroxy group of the newly released 5’ exon 
attacks the 3’ splice site, thereby releasing the lariat and joining the exons.13 
 
Figure 1-2 The chemistry of splicing 
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1.1.2 Alternative splicing and cancer 
1.1.2.1 Regulation of alternative splicing 
Alternative splicing generates multiple mRNAs and the corresponding proteins from a single 
primary transcript, furnishing the complexity of the human proteome. The protein isoforms that 
are generated from the same transcript may have different, or even antagonistic, functions.15-16 
On average, each human gene contains 8.7 exons, and >90% of the genes are alternatively 
spliced.17 Normal cells rely on alternative splicing to adjust protein diversity during development 
and differentiation;18 conversely, misregulated alternative splicing evokes diseases, including 
cancer.19 Indeed, evidence in support of this notion has emerged in many aspects of cancer 
progression, including cell proliferation, programmed cell death, cancer cell metabolism, 
angiogenesis and invasion.20-21  
The alternative splicing pattern can be altered in many different ways (Figure 1-3).22 
Most exons are constitutive and included in the final mRNAs. Cassette exons are sometimes 
excluded from the mRNA (Figure 1-3A). On occasions, multiple cassette exons are mutually 
exclusive –– only one can be selected (Figure 1-3B). Exons can also be shortened or lengthened 
by altering the position of one of their splice sites (Figure 1-3C and D), resulting in alternative 5’ 
and 3’ splice sites. The 5’-terminal exons of an mRNA can be switched through the use of 
alternative promoters and alternative splicing (Figure 1-3E). Similarly, the 3’-terminal exons can 
be switched by combining alternative splicing with alternative polyadenylation sites (Figure 1-
3F). In addition, a failure to remove an intron may occur, causing a splicing pattern called intron 
retention (Figure 1-3G). 
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Figure 1-3 Patterns of alternative splicing 
 
Despite the diverse patterns of alternative splicing, most of the information necessary to 
decide which sections of pre-mRNA will be included is present in the sequence of the pre-
mRNA.23 To understand the complexity of alternative splicing, we must study how changes in 
splice site choice take place. Introns can range from <100 nucleotides (nt) to hundreds of 
thousands of nucleotides. In contrast, exons are generally as short as 50–300 nt (~150 nt on 
average).24 The challenge for correctly choosing the splice sites is that splicing machinery must 
locate small exon sequences within vast stretches of intronic RNA. Although very few patterns 
of alternative splicing have been mechanistically characterized in detail to explain the precision 
they possess, a general outline is understood. Figure 1-4 shows exon definition, a process that 
entails the binding of spliceosomal components on opposite sides of an exon to stimulate the 
excision of an intron.25-26 Factors that can strongly influence this process include splice-site 
strength, exon size and RNA secondary structure.  
Moreover, in most of the complex pre-mRNAs in higher eukaryotes, the intronic 
sequences are not sufficiently conserved for exon definition. Hence, varied regulatory RNA-
binding proteins (RBPs) with RNA sequence specificity also mediate the assembly of snRNPs 
and subsequently stimulate or repress exon inclusion. RBPs bind directly to 5’ or 3’ splice sites, 
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or to other pre-mRNA sequences called exonic or intronic splicing enhancers (ESEs or ISEs) and 
silencers (ESSs or ISSs). The enhancers and silencers stimulate or repress splice-site selection, 
respectively.27-29  
The RBPs that recognize ESEs or ISEs are SR proteins, which contain one or more RNA-
recognition motifs (RRMs) and an arginine/serine-rich (RS) protein-protein interaction domain 
on the C-terminal.30 To date, nine classical SR proteins have been identified, including SRSF1 
(SRp30a), SRSF3(SRp20), SRp30b (SC35), SRp30c, SRp40, SRSF6 (SRp55), SRp54, SRp75 
and 9G8. SR proteins are required at different steps of spliceosome assembly and are constantly 
migrating between nuclear speckles–the subnuclear domains in which certain splicing factors are 
stored–and sites of active transcription.28 To facilitate splicing, they mediate the crucial initiation 
of ‘cross-intron’ and ‘cross-exon’ interactions in both constitutively and alternatively spliced 
pre-mRNAs (Figure 1-4). Briefly, once bound to ESEs or ISEs, different SR family protein 
members recruit U1 snRNP to the 5’ splice sites, forming spliceosome complex E.31 Complex E 
subsequently promotes the splicing factor U2AF65 and U2AF35 to bind to the polypyrimidine 
tract (Yn) and the AG dinucleotide of the upstream 3’ splice site, respectively. In turn, U2AF 
coordinates with SR proteins to recruit U2 snRNP to the branchpoint sequence (A). The exact 
mechanism that SR proteins use to engage both 5’ and 3’ splice site-selection is unclear and is 
still an area of intense investigation. 
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Figure 1-4 Exon definition mediated by splicing machinery and RBPs 
 
On the other hand, ESSs and ISSs are recognized by members of the heterogeneous 
nuclear ribonucleoproteins (hnRNP) family. Unlike SR proteins, which co-localize with other 
splicing factors in nuclear speckles, the hnRNPs are diffusely distributed throughout the 
nucleus.32 Structurally, besides RNA-binding motifs, hnRNPs have auxiliary domains that are 
enriched with unusual distributions of amino acids, which are hypothesized to mediate protein-
protein interactions. In addition, hnRNPs produce strikingly diverse isoforms through alternative 
splicing and post-translational modifications. The resulting complexity of hnRNP family 
members is reasonable given their diverse duties throughout the whole network of gene 
expression, ranging from chromatin-architecture remodeling, telomere maintenance, transcript 
packaging, mRNA export, cytoplasmic mRNA trafficking, pre-mRNA 3’-end processing, and 
alternative splicing, to translation.33 The unifying theme for such functional diversity is the 
inherent DNA/RNA sequence specificity of each hnRNP. Upon tethering to the cis-elements, the 
resulting hnRNP complexes may modulate the accessibility and/or interaction of trans-acting 
factors. In the case of alternative splicing (Figure 1-4), the ESS sequences or ISS sequences 
possibly promote exon exclusion through interacting with hnRNPs bound to distal sites and loop 
formation.34-35 
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1.1.2.2 Splicing regulatory proteins as anticancer drug targets 
In light of their crucial role in regulating alternative splicing, aberrant regulation of RBPs likely 
results in the deregulation of splicing in cancer. In keeping with this notion, deep sequencing has 
revealed that various hnRNPs and SR proteins are expressed in a proliferation-associated 
manner; much higher expression levels were observed in tumor than non-tumor tissues in a wide 
variety of cancers.20, 36 Furthermore, SRSF1, encoding the most well known SR protein SRSF1 
(also called ASF/SF2), was recently described as a proto-oncogene, when its overexpression 
transformed rodent fibroblasts into sarcoma in nude mice.37 The mechanism involved in the 
transformation is likely multifactorial, affecting pathways of proliferation, survival and 
invasion.38 In skin tissue, SRSF6, normally promotes wound healing, can cause hyperplasia when 
overexpressed.39 SRSF3, another newly defined proto-oncogene that encodes the smallest 
member in SR protein family, is amplified in both epithelial carcinoma and mesenchymal tissue 
tumors. The tumorigenic mechanism of SRSF3 involves the overexpression of regulators of 
G2/M transition.40 
More recently, overexpression of core spliceosome components was also observed in 
malignancy. Each spliceosomal snRNP (U1, U2, U4, U5, and U6) consists of a uridine-rich 
small nuclear RNA (snRNA) and seven Sm (Smith) proteins. The Sm proteins (B/B’, D1, D2, 
D3, E, F and G) form a 7-membered ring core structure that surrounds the snRNA. The 
overexpression of these Sm proteins was identified in a large number of tissues from ovarian, 
non-small cell lung carcinoma, and breast cancers. Further, the overexpression was correlated 
with more aggressive phenotypes. Mechanical studies showed that a deletion of Sm proteins led 
to the mammalian target of rapamycin (mTOR)-mediated autophagic cell death in tumor cells, 
while sparing non-tumorigenic cells.41  
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Altogether, these recent discoveries suggest that overexpression of splicing-related 
proteins could be a hallmark of cancer and therefore a therapeutic target. 
1.2 TARGETING SF3B SUBUNIT 1 (SF3B1)  
1.2.1 SFEB1 in constitutive splicing 
The U2 snRNP is a key spliceosome subunit that recognizes the 3’ intronic splice sites during 
spliceosome assembly. Besides U2 snRNA, seven Sm proteins are common to the spliceosomal 
snRNPs. U2 snRNP possesses two unique subcomplexes, splicing factor 3a (SF3a) and splicing 
factor 3b (SF3b), both being required for the interaction between U2 snRNP and pre-mRNA.42 
SF3a is composed of three subunits of 60, 66, and 120 kDa;43 SF3b consists of SF3B1 (SAP155), 
SF3B2 (SAP145), SF3B3 (SAP130), SF3B4 (SAP49), SF3B5 (10 kDa), SF3B14 (p14) and 
PHF5A.44-47  
Among the SF3b components, the amino acid sequence of SF3B1 is highly conserved 
from Schizosaccharomyces pombe (52.4% identity) to human (99.6%) and composed of two 
regions: the N-terminal domain (NTD, amino acids 1–430) and C-terminus (amino acids 431–
1304). The C-terminus shows even higher identity and comprises 22 tandem HEAT (Huntington, 
Elongation Factor 3, PR65/A, TOR)-like repeats, each consisting of approximately 40 amino 
acids to afford two antiparallel α-helices. These HEAT repeats are essential for protein-protein 
interactions, wrapping around––hence stabilizing––several other components of the U2 snRNP 
(Figure 1-5).48 The N-terminal of SF3B1 is less conserved and has binding sites for splicing 
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factors U2AF65, U2AF35,49 and SF3B14,46 as well as for the regulatory proteins cyclin E50 and 
Nipp151, which mediate the phosphorylation of SF3B1.  
SF3b facilitates the stable assembly of U2 snRNP, an early event during spliceosome 
formation that requires both RNA-RNA and protein-RNA interactions with 3’ end of the intron. 
SF3B14 and SF3B149 are the SF3b components that directly bind pre-mRNA. SF3B14 binds to 
the branchoint adenine. SF3B1 wraps SF3B14 inside so that it accurately localizes on the 
adenine (Figure 1-5).52-53 Further downstream on the intron, U2AF65 binds the polypyrimidine 
tract and U2AF35 binds the 3’ splice site. The N-terminus of SF3B1 forms an elongated, 
unstructured conformation that extensively interacts with U2AF65 and U2AF35 for efficient 
recruitment of other U2 snRNP components.54-55 Of note, U2AFs rely on an RNA recognition 
motif (RRM) to bind their partners; these RRMs are accordingly named U2AF-homology motifs 
(UHMs).56 U2AF UHMs recognize tryptophan-containing linear peptide motifs, so-called UHM-
ligand motifs, which were identified in SF-1 and SF3B1.54, 57-58 SF3B1 was predicted to have 
five HLMs, indicating that it might be involved in extensive protein-protein interactions. 
Collectively, these conserved interactions coordinate the assembly of early complexes of a 
spliceosome and might have more profound implications in alternative splicing regulation, where 
similar protein-protein interactions are desired.  
 
Figure 1-5 SF3B1 mediates U2 snRNP assembly in constitutive splicing 
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SF3a and b complexes are also believed to mediate the timing for catalytic activation of 
splicing complexes.59-60 This is reinforced by the fact that SF3B1 is the only U2 component 
known to experience reversible phosphorylation concomitant with, or right after, the first 
catalytic step.61-63  
Altogether, SF3B1 acts as a modulator of the integrity of U2 snRNP by interacting with 
multiple snRNP and non-snRNP proteins; it might be a key switch for the whole splicing 
machinery for faithful 3’ pre-mRNA binding.  
1.2.2 SF3B1 in alternative splicing  
As explained above, the sequence selectivity of SF3B1 during constitutive splicing is achieved 
through protein-protein interactions. SF3B1 may broadly interact with splicing factors to regulate 
alternative splicing events. However, accumulating evidence indicates SF3B1 might function as 
an independent splicing factor to regulate alternative splicing as well as will be discussed as 
follows. 
The sequence specificity of SF3B1 as a trans-acting splicing factor was first discovered 
in the alternative splicing regulation of B-cell lymphoma 2 (Bcl-2) family member Bcl-x in 
response to ceramide. Bcl-2 family proteins control programmed cell death (apoptosis)-mediated 
cell fate. Bcl-x generates anti-apoptotic Bcl-xL and pro-apoptotic Bcl-xS via the alternative 
selection of 5’ splice sites. This study demonstrated that phosphorylated SF3B1 binds to 
ceramide-responsive cis-element 1 (CRCE-1) upstream of the alternative 5’ splice site, thereby 
blocking the selection of the alternative proximal 5’ splice site that generates Bcl-xS (Figure 1-6). 
Ceramide activates protein phosphatase 1 (PP1), which dephosphorylates SF3B1, releasing the 
alternative 5’ splice site. Accordingly, knockdown of SF3B1 decreased the ratio of Bcl-xL/Bcl-xS 
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and sensitized A549 lung cancer cells to the chemotherapeutic agent daunorubicin. This study 
provided the first proof that SF3B1 exhibits sequence-specific binding in alternative splicing 
regulation; down-regulation of U2AF65, SF3B2, SF3B3, SF3B4, the splicing factors typically 
interacting with SF3B1 in constitutive splicing, did not affect the splicing pattern of Bcl-x.64  
 
Figure 1-6 SF3B1 regulates Bcl-x alternative splicing in response to ceramide signaling 
 
In addition to direct binding to RNA sequences, SF3B1 was also shown to mediate 
alternative splicing through protein-protein interactions. Sattler and coworkers demonstrated the 
significance of the structural units for SF3B1 to regulate alternative splicing. Specifically, by 
selective binding to SF-1, U2AF65, and splicing factors SFP45 or the poly(U)-binding-splicing 
factor (Puf60) via different HLMs, SF3B1 regulates the alternative splicing of the apoptosis 
regulatory gene FAS, resulting in exon 6 skipping.65-66 Among these binding partners, Puf60 
might also play a role in spliceosome assembly by replacing SF1 from the branch point and then 
acting as a loading dock for SF3B1 to recognize/bind to U2AF65.67 A splicing variant of Puf60, 
the far-upstream element (FUSE)-binding protein-interacting repressor (FIR), represses c-myc 
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transcription by suppressing the TFIIH/P89/XBP helicase. In colon cancer tissues, enhanced 
expression of SF3B1 increases both FIR and FIRΔexon2, a splicing variant of FIR without the 
transcriptional repression domain. In turn, FIRΔexon2 interacts with FIR and SF3B1, disturbing 
their c-myc expression suppressing and splicing regulatory functions, respectively.68-70 SF3B1 
knockdown decreased the expression of c-myc, apparently by breaking up the FIR/ 
FIRΔexon2/SF3B1 complexes.  
Besides these genes verified through biological approaches, small-molecule modulators 
of SF3b significantly expanded the pool of target genes regulated by SF3B1, as will be discussed 
in detail later. Considerably more cancer-related genes are under the surveillance of key splicing 
factors like SF3B1 at the alternative splicing level. For that reason, targeting splicing factors may 
become a new generation of chemotherapeutic strategy. 
1.2.3 SF3B1 alterations in cancer 
Unlike other oncogenic splicing-related proteins, the only type of genetic alteration in SF3B1 in 
diseases is somatic mutation, which has been mainly studied in hematologic malignancies since 
2011. The first SF3B1 somatic mutation was observed in myelodysplastic syndromes (MDSs). 
MDSs are heterogeneous hematologic cancers characterized by low blood cell counts (mostly 
anemia) and a risk of progression to acute myeloid leukemia. Pre-mRNA splicing-related genes 
are recurrently mutated in >60% of MDS patients, and in up to 87% for those with high-count 
ring sideroblasts.71-72 Interestingly, the mutations are invariably heterozygous substitutions and it 
appears SF3B1 mutation is associated with longer survival free of disease.73  
In chronic lymphocytic leukemia (CLL), the most common adult leukemia in Western 
countries, SF3B1 mutation also ranks as the most frequently mutated gene, ranging from 5% –
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18% depending on the composition of the cohorts. In striking contrast to MDS, SF3B1 mutation 
has been consistently correlated with poorer clinical outcomes.74 Temporally, SF3B1 mutation 
occurred only in certain populations of tumor cells, indicating that it appeared later in the disease 
development, promoting the malignancy’s progress instead of initiating it.75 In the future, SF3B1 
mutation might be incorporated into prognostic schema in combination with current biologic 
markers to better predict CLL progression. Meanwhile, when knocked out in mouse embryos and 
silenced with shRNA in human cell (HEK293T) models, SF3B1 was also shown to be essential 
for cell survival.76-77  
The mutations within SF3B1 are mainly located at six hotspot codons E622D, R625H, 
H662D, K666E, K700E, and G742D; K700E accounts for over 50% of the cases. Combined with 
other less common mutations, they are all located in the conserved C-terminal region, clustering 
between the fifth and eighth HEAT repeats. Quesada et al. constructed a tentative model of 
SF3B1 and suggested that these hotspot mutations might occur at the inner surfaces of the 
structure (Figure 1-5), where interactions between SF3B1 and its binding partners occur.75 The 
mutated amino acids were predicted to be spatially adjacent to one another. Hence, these 
mutations might have the similar functional impact of significantly disturbing the normal 
protein-protein interactions of SF3B1. SF3B1 mutation was also detected in 3 out of 77 breast 
cancer patients (2 K700E and 1 K666E),78 4 our of 99 pancreatic cancer patients (1 R568H, 1 
Q699H and 2 K700E)79 and 19 out of 102 uveal melanoma patient (all R625C).80  
The causative link between SF3B1 mutation and tumorigenesis is still elusive. The co-
occurrence of SF3B1 alteration and these malignancies further supports this splicing factor as a 
cancer therapeutic target. In CLL, SF3B1 was recently categorized as a proto-oncogene.76  
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1.2.4 SF3b modulators 
The modulation of core spliceosomal components would most likely result in a loss of critical 
proteins and expression of splice variants with aberrant functions; therefore, inhibiting 
spliceosomal components would be a highly deleterious event in all cells. However, as will be 
explained here in detail, using SF3b as an example, spliceosome modulators generally affect 
selective subgroups of genes in a tumor-specific manner.81 This selectivity supports further 
exploiting alternative splicing as a new class of tumor vulnerability.  
Up to now, three bacterial natural products, FR901464,82-84 pladienolides85-86 and 
herboxidiene/GEX1A,87 have been confirmed to target SF3b. These three originated from 
distantly related bacterial genera (FR901464 and herboxidiene from Pseudomonas sp. and 
pladienolides from Streptomyces sp.). Ironically, bacterial genomes are devoid of introns as well 
as the genes that code for spliceosomal components. 
1.2.4.1 FR901464 and its analogs 
In 1996, FR901464 was by the Fujisawa Pharmaceutical Company from Pseudomonas sp. No. 
2663 in efforts to discover transcription factor modulators. FR901464 exhibited antiproliferative 
activity against human solid tumor cell lines as well as against murine tumors in mice.82-84 
Phenotypic characterization of the cells exposed to FR901464 showed that FR901464 increased 
the expression of SV40 promoter-driven reporter genes stably expressed in MCF-7 breast cancer 
cells (M-8), arrested cell cycles at G1 and G2/M phases, and induced internucleosomal DNA 
fragmentation. These distinctive phenomena are similar to those caused by histone deacetylase 
inhibitors.88 Soon it was confirmed that this molecule, unlike histone deacetylase inhibitors, did 
not caused an accumulation of acetylated histones, indicating a novel unknown mode of action.89  
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The interesting biological profile of FR901464 uncovered from these preliminary studies 
has prompted researchers to synthesize this natural product. The Jacobson group reported the 
first total synthesis of FR901464 in 2001.90 The Kitahara group reported second and third 
syntheses of FR901464, and subsequently prepared spliceostatin A and its biologically active 
biotinylated probe.91-93 More recently, the Koide group synthesized FR901464 and obtained two 
analogs –– meayamycin and meayamycin B (Figure 1-7) –– that are at least two orders of 
magnitude more potent than FR901464 in terms of antiproliferative activity in in vitro models, 
with GI50 as low as single digit picomolar.94-95 In 2013, the Ghosh group reported a more concise 
enantioselective synthesis of FR901464 in 10 linear steps.96 
 
Figure 1-7 Structures of FR901464 and its derivatives 
 
In 2013, the Cheng group discovered two groups of FR901464-related natural product. 
Thailanstatin A (Figure 1-8),97 isolated from the culture broth of Burkholderia thailandensis 
MSMB43, differs from FR901464 in that it lacks a destabilizing hydroxyl group on C17 and has 
a methylene group instead. Moreover, in pH 7.4 buffer at 37 °C, more than 60% of thailanstatin 
A remained after 78 h, while FR901464 decayed to and remained at a total level of 38%. 
Furthermore, thailanstatin A was shown to be equipotent in its in vitro splicing inhibition and 
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anti-proliferative activity in comparison to FR901464. Serendipitously, while trying to purify 
FR901464 from Psudomonous sp. 2663 as a reference for the characterization of thailanstatins, 
Cheng et al. isolated spliceostatin B (Figure 1-8).98 Compared with FR901464, spliceostatin B is 
missing a hydroxyl group on C4. Similar to thailanstatins, the hydroxyl moiety at C17 is 
substituted with a carboxyl moiety on spliceostatin B. In addition, the epoxide on C3 is replaced 
by a terminal methylene moiety. Clearly, multiple substitutions on spliceostatin B, such as C3 
and C4, were deleterious to its potency, since it was nearly three orders of magnitude less potent 
than FR901464. 
 
Figure 1-8 Structures of thailanstatin A and spliceostatin B 
 
In 2005, FR901464 was identified with inhibitory activity against transmembrane 
thioredoxin-related protein, which has not been proved by further investigations.99 In 2007, 
Yoshida and coworkers discovered that spliceostatin A (SSA), a methoxy ketal analog of 
FR901464, targeted the SF3b subcomplex of the spliceosome U2 snRNP.100 The specific binding 
target within this complex was elusive, but it was presumed to be SF3B1 or SF3B3. FR901464 
and its analogs targeted the SF3b sub-complex and subsequently blocked splicing before the first 
transesterification reaction.100 Roybal and Jurica used splieceostatin A to show that besides being 
critical for spliceosome assembly, the SF3b sub-complex was required for the maturation of the 
spliceosome from complex A to B.101 This conclusion, however, is questionable because the 
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concentration of heparin in the quenching buffer for the in vitro splicing reactions was much 
lower than required (0.125 mg/mL versus 1.25 mg/mL or higher). Such defected procedures 
would inevitably cause nonspecific binding of components in the nuclear extract to the 
negatively charged pre-mRNA substrates.102 
In 2011, Valcárcel et al. proved that spliceostatin A prevented the correct base-paring 
between U2 snRNA and pre-mRNA branch point via an interruption of the SF3B1 function, 
bringing our understanding of the impact of SF3b inhibition on spliceosome dynamics to another 
level. In addition, this study also unveiled that when spliceostatin A binds to SF3B1, sequences 
at 5’ upstream of the branch point are invariantly selected as alternative binding partners to U2 
snRNA, with varying sequence-dependent affinity. In HeLa cells, spliceostatin A (3-h exposure) 
mimicked the effect from SF3B1 siRNA and altered alternative splicing of  ~2% of the 
endogenous genes that were examined by a splicing-sensitive microarray. A majority of the 
affected genes code for cell cycle-related proteins, which is consistent with the results from the 
knockdown of spliceosome components.40, 100, 103 
Spliceostatin A inhibited in vitro splicing, accumulating pre-mRNA at nuclear 
speckles.100 Through an unknown mechanism, spliceostatin A resulted in the production of a C-
terminally truncated product of p27 splice variant with a retained intron 1. This truncated variant 
evaded nonsense-mediated mRNA decay (NMD), leaked into cytoplasm, and was translated into 
protein. Both of these p27 isoforms blocked the G1 to S phase transition by inhibiting cyclin-
dependent protein kinases (CDKs). The mechanism of the leakage is clearly related with the 
inhibition of SF3b via an unknown mechanism. 
A misprocessed RNA molecule is subject to NMD because of a premature termination 
codon. If an intron is retained after splicing, an in-frame stop codon (either UAA “ochre” or 
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UGA “opal”) will likely appear in the splicing product because of the consensus sequence 
AG/GURAGU (R = A or G) on the intronic 5’ splice sites. When such a stop codon is >50 nt 
upstream of the final exon-exon splice junction in the mRNA transcript, a premature termination 
codon is defined and this mRNA becomes an NMD candidate. Growing evidence suggests that 
the coupling of alternative splicing and NMD provides a prominent means of gene expression 
regulation.104 Accompanying the regulation of alternative splicing by spliceostatin A, the 
introduction of premature termination codon causes widespread NMD and subsequent decreased 
mRNA and protein levels.105 Therefore, SF3b inhibition would produce diverse genes that are 
subject to NMD.  
The cytoplasmic leakage of abnormally spliced pre-mRNA might play a role in the 
cytotoxicity caused by SF3b inhibitors. In support of this notion, it was discovered that splicing 
factors, crucial for early spliceosome assembly, directly interact with RNA binding proteins from 
the exon junction complex (EJC). EJCs are typically assembled ~20 to 24 nt upstream of splice 
junctions and are in charge of mRNA export in the NMD pathway. In nematode Caenorhabditis 
elegans, depletion of any of the core components of an EJC, which is typically left on the spliced 
mRNA for exporting mRNA into cytoplasm, leads to cytoplasmic leakage of unspliced RNAs. 
Importantly, several splicing factors, including SF3b complex, interact with key EJC subunits.106 
The actions of FR901464 thus probably interfere with a correct coupling of alternative splicing 
and the NMD pathway, mimicking the deletion of these EJC subunits. In turn, EJCs can 
influence alternative splicing. Core (Y14 and eIF4A3) and auxiliary (RNPS1, Actin, and SAP18) 
components of EJCs promote the proapoptotic Bcl-xS, Bim, Mcl-1.107 All together, these data 
present FR901464 derivatives as attractive chemical tools to probe the complex interaction 
between splicing and RNA surveillance mechanisms. 
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As another significant example of the splicing modulatory effect of spliceostatin A, 
Yoshida et al. demonstrated that spliceostatin A impaired the expression of vascular endothelial 
growth factor (VEGF) at both mRNA and protein levels in cervical cancer HeLa cells.108 
Specifically, at the RNA level, both splicing and transcription were inhibited by spliceostatin A, 
but its effects on the alternative splicing was elusive since the short variant (VEGF165b) was 
undetectable. For the translation pathway, spliceostatin A suppressed both initiation and 
elongation by an unknown mechanism that blocked the phosphorylation of the C-terminal 
domain of polymerase II. This suppression of VEGF was sufficient to inhibit angiogenesis in 
vivo. Furthermore, a global gene expression in HeLa cells using a DNA microarray revealed that 
nearly 25% of genes were downregulated when exposed to spliceostatin A for 3 h, indicating the 
existence of a previously unappreciated level of coupling of splicing and transcription pathways.  
1.2.4.2 Pladienolides, E7107 and their analogs 
Pladienolides (first reported in 2004) are seven 12-membered macrolides identified from 
Streptomyces platensis Mer-11107 via a cell-based assay for suppressing hypoxia-induced, 
human VEGF promoter-mediated expression.85 Similar to FR901464, pladienolides arrest cells at 
the G1 and G2/M phases. The most potent pladienolides B and D (Figure 1-9), exhibited low 
nanomolar range IC50 in inhibiting the growth of a variety of cancer cell lines and even caused 
tumor regression in several human cancer xenograft models, demonstrating a broad therapeutic 
window. A COMPARE analysis of a panel of 39 human cancer cell lines indicated a mode of 
action different from current anticancer drugs.86 E7107, a urethane derivative of pladienolide D 
that showed enhanced in vivo potency and pharmacochemical properties, quickly advanced to 
phase I a clinical trial for solid tumors.109-111  
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Figure 1-9 Structures of pladienolides and their analogs 
 
Kotake et al. completed the first total synthesis of pladienolides B and D.112 
Subsequently, by using 3H-labeled, BODIPY-tagged, and photoaffinity- and biotin-tagged 
pladienolide B derivatives, they discovered that SF3B3, from the SF3b subcomplex, was the 
binding target of pladienolides. However, they could not eliminate the possibility that the 
compound can fit into a binding pocket composed of SF3B1 and SF3B3.111 As a support for the 
importance of SF3B1, colorectal cancer cell lines WiDr and DLD1 with acquired resistance to 
pladienolide B developed the same R1074H mutation in SF3B1.113 These arginines are required 
for the conformation of HEAT repeats during protein-protein interactions.114 Therefore, this 
mutation likely alters the crucial conformation of the C-terminal of SF3B1. Taken together, the 
divergent conclusions about the specific binding target of pladienolides indicate that 
pladienolides may bind to an interface of multiple SF3b components. 
The necessity of epoxide for the activity of pladienolides has been debated. Recently, via 
synthesizing analogs of a pladienolide-like natural product FD-895 (Figure 1-9), Burkart et al. 
showed that replacing the epoxide with cyclopropane stabilized the compound with moderate 
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compromise of the potency, indicating the dispensability of epoxide for pladienolide.115 This is 
in contrast to the epoxide of FR901464––the same substitution led to a complete abrogation of 
the biological activity of FR901464.90 This discrepancy in the importance of the epoxide moiety 
between the derivatives of FR901464 and pladienolides is non-trivial and needs to be fully 
elucidated. 
1.2.4.3 Sudemycins 
The structural complexity of FR901464 and pladienolides has considerably hindered the 
synthetic efforts to improve their stability, potency, and their application in extensive biological 
studies. Interestingly, Webb et al. reported that although structurally dissimilar, FR901464 and 
pladienolides shared common key features that could be overlapped in low energy conformation 
in three-dimensions. These features include a carbonyloxy group (two hydrogen-bond acceptors), 
a well-restrained (hydrophobic) diene linker, and a secondary epoxide (a nucleophilic hydrogen-
bond acceptor). Hence, a series of derivatives of FR901464, called sudemycins (the most active 
analogs shown in Figure 1-10) were synthesized, which are much more synthetically accessible 
(bearing only three of the nine stereocenters in FR901464) with improved stability. Importantly, 
they retained the biological activities of the parent compounds, including splicing inhibition and 
cell cycle arrest. Preliminary SAR analyses afforded analogs with IC50 in the range of ~80 – 500 
nM against various cell lines, especially in mantle cell lymphoma.116-117 Sudemycins also 
regulated alternative splicing of MDM2, caspase 2, and caspase 9, but not Bcl-x, in vitro and in 
vivo. It appeared that the regulation of MDM2 alternative splicing is more prominent in cancer 
cells versus normal myoblast cells (LHCN-M2), which might result from a relatively lower 
baseline expression of this gene in normal cells.81  
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Subsequently, the Webb group chose to screen for potential combinations using 
sudemycin D6 (low double-digit nanomolar IC50 values, structure shown in Figure 1-10) in in 
vitro and in vivo melanoma models. It synergized with a dual inhibitor of phosphatidylinositol-3-
kinase/mammalian target of rapamycin (PI3K/mTOR) BEZ235, and epoxide hydrolase 
inhibitors. The epoxide hydrolase inhibitors presumably enhanced the stability of sudemycins.118  
 
Figure 1-10 Structures of sudemycin F1 and D6 
 
1.2.4.4 Herboxidiene/GEX1A 
Herboxidiene (Figure 1-11) was originally isolated in 1992 from Streptomyeces chromofuscus 
A7847 as an herbicide.119 In 1997, Koguchi and colleagues implemented a luciferase reporter 
driven by a low density lipoprotein receptor promoter stably transfected into Chinese hamster 
ovarian cells and identified herboxidiene and trichostatain A from a butanol microbial extract.120  
 
Figure 1-11 Structure of herboxidiene 
 
In 2002, herboxidiene was isolated as an anti-tumor agent. This compound arrested the 
cell cycle at the G1 and G2/M phases of human normal fibroblast cells WI-38 and activated the 
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expression of the luciferase reporter driven by the promoters of E2F, c-myc, DNA polymerase α, 
c-fos, Interleukin 2 (IL-2) and SV40 early genes in human osteosarcoma cell line Saos-2. The 
strength of gene activation activity of the compounds correlated with that of their cytotoxicity. 
Unexpectedly, herboxidiene decreased the level of endogenous genes including E2F-1 (cell 
cycle-related transcription factor gene), cdc2, cyclin D1, cyclin A (cell cycle related kinase 
genes), p21/waf1, p27/kip1 (inhibitors of cell cycle related kinase genes), cdc25A (cell cycle 
related phosphatase gene), Bcl-xL, Bax (apoptosis-related genes), c-myc and c-fos (cell 
proliferation-related genes) at sub- to single digit micromolars after a 2–8 h exposure. 
Particularly with cdc25A, a shorter product of unknown identity was induced by herboxidiene 
post an 8-h treatment, with a simultaneous decrease in the major product, indicating a regulation 
of alternative splicing by herboxidiene.87, 121 
In 2011, Mizukami and coworkers identified SF3B1 as the molecular target of 
herboxidiene and demonstrated its function as a splicing inhibitor.122 In contrast to their reports 
in 2002, herboxidiene induced the production of C-terminal truncated p27 (so called p27*) by 
intron 1 retention. P27* was also found to be a functional inhibitor of cyclin E-Cdk2, like its full-
length counterpart p27, but is not targeted for degradation by the proteosome. Most importantly, 
a photoaffinity-labeled derivative labeled SF3B1 as the only target of herboxidiene.  
1.2.5 Summary  
The biological studies of SF3b inhibitors reveal the extent and significance of the influence that 
spliceosomal components have in the expression of subgroup of human genes, especially in 
cancer biology. Progress in the regulation of alternative splicing has been benefiting from the 
efforts using both biological and chemical tools. Known human genes under the regulation of 
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SF3b components, especially SF3B1, are summarized in Table 1-1. Modulating the 
corresponding splicing-regulatory proteins, therefore, can allow for novel therapeutic targets to 
reverse the cancerous phenotype caused by these misregulated genes.  
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Table 1-1 Human genes controlled by SF3b components 
Gene 
product 
Function Cellular pathway Experimental tools (condition) References 
p27/kip1 
Kinase inhibitor 
Cell cycle 
(CDK-cyclin) 
SSA (14 h) 100 
p21/waf1 FR (16 h)/Herb (2 h) 84, 87 
E2F-1 Transcription factor Herb (8 h) 87 
Cdc25A Phosphatase Herb (2 h) 122 
Cdc2 Kinase Herb (8 h) 87 
Cyclin D1 Kinase Herb (8 h) 87 
IκBα NFκB inhibitor 
Cell cycle 
(transcription) 
SSA (14 h) 100 
c-myc Transcription factor SF3B1 siRNA (72 h)/FR (48 h) 68, 84 
FIR Transcription 
suppressor 
SF3B1 siRNA (72 h)/SSA (48 h) 68, 84  
VEGF Angiogenesis Microenvironment SSA (6 h) 108 
Bcl-x 
Apoptosis-related Cell death 
SF3B1 siRNA (24 h)/Herb (8 h) 64, 87 
Mcl-1 SF3B1 siRNA (24 h) 123 
FAS SF3B1 deletion-mutation (24 h) 65 
MDM2 sudemycins (8 h) 81 
Caspase-9 sudemycins (8 h) 81 
Caspase-2 sudemycins (8 h) 81 
Bax Herb (8 h) 87 
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2.0  SF3B MODULATOR MEAYAMYCIN B FOR CANCER THERAPY 
2.1 MEAYAMYCIN B––POTENT SPLICING MODULATOR  
This section is taken from “Gao, Y., Vogt, A., Forsyth, C. J., and Koide, K. (2013) Comparison 
of splicing factor 3b inhibitors in human cells, ChemBioChem 14, 49-52.” 
2.1.1 Research Design 
The correct assembly of spliceosomal snRNPs, especially U1 and U2 snRNPs that respectively 
define the locations of spliceosome on 5’ and 3’ splice sites of introns, onto pre-mRNAs is 
essential for pre-mRNA splicing. The binding fidelity of U2 at 3’ splice site relies on the U2-
associated SF3b subcomplex. In 2007, the SF3b complex was found to be directly inhibited by 
FR901464,100 a natural product isolated from the culture broth of a bacterium of Pseudomonas 
sp. No.2663 (Figure 1-7).83 Since then, some of the readily available FR901464 analogs — 
spliceostatin A92 and meayamycin124, among others81, 116-117 — have been widely used to 
elucidate the mechanisms of pre-mRNA splicing and SF3b-related diseases.100-101, 105, 108, 125-134 In 
2011, herboxidiene (a.k.a., GEX1A)87, 121 was also found to be an inhibitor of SF3b,119, 122 and 
our group reported meayamycin B as a new FR901464 analogue.  
Meayamycin B was more synthetically accessible than meayamycin and the most potent 
among the known FR901464 analogs as an antiproliferative agent;94, 135 however, it has not yet 
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been studied as a splicing inhibitor. Meanwhile, despite their widespread use, FR901464 analogs 
have not been directly compared within the same splicing system. With the addition of new SF3b 
inhibitors such as meayamycin B and herboxidiene, a direct comparison of these two 
compounds, FR901464, spliceostatin A, and meayamycin in a splicing assay would enable 
rational selection of an SF3b inhibitor for specific experimental designs.  
In addition, it should be noted that there appears to be confusion in the literature about 
the identity of FR901464 analogs. For example, in a recent review article, FR901464, 
spliceostatin A, and meayamycin were listed as if they were unrelated compounds.136 Both 
spliceostatin A and meayamycin are synthetic analogs of FR90146492 and should be treated as 
such129, 137-138 and not as natural products.139 
2.1.2 Results and Discussion 
2.1.2.1 Cell-based splicing inhibition assay  
In this study, we used a splicing reporter developed by the Moore group (Figure 2-1).129 Briefly, 
this screening construct consists of an exon 6-intron 6-exon 7 cassette from the human triose 
phosphate isomerase (TPI) minigene upstream of a firefly luciferase open reading frame. To 
ensure that the expressed luciferase activity is positively correlated with the splicing inhibitory 
capability of the test compounds, the constitutive in-frame stop codon in the intron was removed 
and a G was inserted in TPI exon 7 so that the downstream luciferase gene is in-frame when the 
intron is retained.  
In addition to the screening construct, there are also positive and negative controls 
(Figure 2-1). A negative control construct contains the same minigene but with a mutated 5ʹ′-
splice site; therefore, it constantly expresses high levels of luciferase. A positive control contains 
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unmodified TPI minigene and a functional luciferase is translated only when the intron is 
spliced. These constructs were stably transfected into the human embryonic kidney 293 
(HEK293) cell line, and the resulting cell lines were called HEK293-II and HEK293-III, 
respectively.  The Z-scores of a splicing assay using HEK293-II paired with HEK293-III were 
reported.129 However, the Z-score of an assay using the HEK293-II cell line by itself and a potent 
SF3b inhibitor as a positive control for splicing inhibition has not been reported. 
 
Figure 2-1 TPI minigene constructs for splicing inhibitor screening 
 
To configure the cellular assay for compound screening using a small-molecule control, 
we set out to further optimize and validate the HEK293-II-based splicing assay to meet the 
accepted high throughput criteria in a 96-well format.140 To this end, meayamycin B was chosen 
as a pre-mRNA splicing inhibitor because it is the most potent among known FR901464 analogs 
against various human cancer cell lines and is structurally similar to the known splicing 
modulators meayamycin, spliceostatin A, and FR901464.94 To find a convenient end-point of the 
splicing assay, the inhibitory activity of meayamycin B (10 nM, ED95) and DMSO (0.5% v/v) 
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was monitored over time. This study revealed that meayamycin B caused a linear increase in 
luciferase activity that plateaued at around 36 h. Sixteen hours was the shortest period of 
exposure that was in the linear range of the curve, showing a reasonably large signal-to-
background ratio (Figure 2-2A); hence, 16 h was chosen for further assay development. It is 
noteworthy that our assay system did not include HEK293-III (negative control) cell line, but a 
dose-dependence study showed that a 16-h exposure of meayamycin B elicited negligible 
increase of luciferase activity, indicating the absence of other influence such as transcription and 
translation (Figure 2-2B).  
 
Figure 2-2 Meayamycin B in HEK293-II and HEK293-III 
 
We then determined the optimal cell density at the 16-h time point. In the presence of 
meayamycin B (10 nM, ED95), luciferase activity showed a linear correlation with cell numbers 
over a wide range of cell densities. We chose 1.6×104 cells per well as judged by the lowest 
standard deviation of luciferase expression (Figure 2-3A, left panel) and a calculated coefficient 
of variation of less than 7% (Figure 2-3A, right panel). This optimal cell density was in 
agreement with previously reported data in a 384-well format.129 
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Meayamycin B is also an antiproliferative agent; therefore, we assessed the growth 
inhibition of the HEK293-II cells by meayamycin B to ensure that the luciferase data would not 
be skewed by cell growth inhibition, and therefore would truly reflect the splicing inhibition. To 
this end, we employed a total protein assay using bicinchoninic acid (BCA) and a cell 
proliferation assay using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium inner salt (MTS) after a 16-h incubation of HEK293-II cells with 
meayamycin B (10 nM). The BCA assay was used to assess cell proliferation because in our 
experiments, cell number correlated with total protein concentrations (Figure 2-3B). 
Meayamycin B (10 nM) induced a 15% inhibition of growth in HEK293-II cells (Data not 
shown). Hence, further luciferase assays were normalized with total protein concentrations. 
 
Figure 2-3 Optimization of cell density 
 
With the optimized conditions in hand, we proceeded to determine the Z-score of the 
splicing inhibition assay. The HEK293-II cells (1.6×104 cells per well) in 96 wells were treated 
with meayamycin B (10 nM) or DMSO for 16 h. As shown in Figure 2-4, a half-plate 
minimum/half plate maximum signal design produced a Z-score of 0.56±0.04 (n = 3), validating 
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high throughput compatibility.140-141 Dotted lines for each set of data indicate 3 × standard 
deviations.  
 
Figure 2-4 Z-factor calculation of the splicing inhibition assay in a 96-well format   
 
2.1.2.2 Evaluation of natural and synthetic SF3b inhibitors 
With this validated method, we investigated the potencies of FR901464, spliceostatin A, 
meayamycin, meayamycin B, and synthetic142 herboxidiene. As shown in Figure 2-5A, 16-h 
treatments with these compounds resulted in a dose-dependent splicing inhibition with ED50 
values of 3.5±0.75, 4.7±1.7, 1.6±0.4, 0.23±0.12, and 257±11.1 nM, respectively. The relative 
luminescence unit (RLU) is defined as the ratio of luminescence intensities from compound-
treated and DMSO-treated normalized by the corresponding cell density. Data points represent 
average values of triplicate experiments±standard deviations. The splicing inhibition was further 
verified by a semi-quantitative RT-PCR experiment that showed the relative amounts of both 
spliced and unspliced TPI mRNA (Figure 2-5B). In both assays, meayamycin B was found to be 
the most potent splicing inhibitor among the compounds tested. 
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Figure 2-5 Splicing inhibition of TPI minigene by SF3b inhibitors for 16 h  
 
We next studied the time-dependence of splicing inhibition using the ED95 concentrations 
calculated from the 16-h assays. Since these compounds are potent antiproliferative agents, cell 
viability (see Figure 2-6A) under each treatment was measured and factored into the evaluation 
of splicing inhibition over time. As shown in Figure 2-6B, the luciferase activity (i.e., splicing 
inhibitory activity) increased to a similar extent (relative luminescence unit, RLU = 5–10-fold 
increase over vehicle control) for the first 24–48 h in the presence of FR901464, spliceostatin A, 
and herboxidiene before it dropped back to near baseline in 72 h. The magnitude of luciferase 
activity was much larger in the presence of meayamycin and meayamycin B (RLU = 20–30-fold 
increase over vehicle increase) and remained as such for 72 h. We postulated that the prolonged 
effect of the meayamycins was partly due to their superior stability in cell culture medium.124, 143 
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Figure 2-6 Time-dependence of splicing inhibition by SF3b inhibitors 
 
Thus far, we have discussed FR901464, its analogs, and herboxidiene as SF3b inhibitors. 
However, these compounds are also antiproliferative agents.83-84, 87, 91, 117, 121-122, 135, 143 
Surprisingly, the relationship between these two activities has not been evaluated by the Pearson 
correlation. To determine how well splicing inhibition and cell growth inhibition caused by 
meayamycin B and herboxidiene correlate with each other, HEK293-II cells were exposed to 
meayamycin B and herboxidiene for 16 h, and the luciferase activity and cell proliferation were 
measured. The results are shown in Figure 2-7. The Pearson correlation coefficients (r) for 
meayamycin B and herboxidiene were determined to be -0.944±0.01 (p < 0.0001) and -
0.603±0.17 (p < 0.0008), respectively. Therefore, the splicing inhibition and antiproliferative 
activities for both compounds are correlated in these transformed HEK293 cells, with a stronger 
correlation for meayamycin B. 
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Figure 2-7 Correlation between splicing inhibitory and antiproliferative activities 
 
2.1.2.3 Are simple electrophiles sufficient to inhibit splicing? 
Many of the natural products that inhibit pre-mRNA splicing (FR901464,100 pladienolides,111 
herboxidiene,122 and isoginkgetin129) are endowed with either an epoxide or a Michael acceptor. 
However, a complete understanding of these important electrophilic functional groups remains 
elusive.90 Thus, we screened a panel of epoxides and Michael acceptors (Figure 2-8) in the 
HEK293-II-based assay; none of these compounds inhibited splicing (1, 10, and 50 µM) as 
determined by the luciferase assays and RT-PCR analysis. These results indicate that an 
electrophilic functional group by itself is not sufficient to inhibit pre-mRNA splicing. 
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Figure 2-8 Epoxides and Michael acceptors do not inhibit splicing 
2.1.3 Conclusion 
We implemented a previously reported cell-based splicing assay system in a 96-well format 
using meayamycin B as a positive control. The validated assay permitted a direct, quantitative, 
and comparative evaluation of the currently available analogs of FR901464 and herboxidiene for 
an inhibition of constitutive splicing activity. The assay delivered graded responses and ED50 
values for all agents; meayamycin B was the most potent, while meayamycin, spliceostatin A, 
and FR901464 were equipotent, and herboxidiene was the least potent. Meayamycins inhibited 
pre-mRNA splicing for longer periods than spliceostatin A, FR901464, and herboxidiene. 
Antiproliferative activity and splicing inhibition by meayamycin B were strongly correlated. 
Moreover, we found that simple electrophilic functional groups did not suffice for splicing 
inhibition in HEK293-II cells. Our data validate meayamycin B as the most potent spliceosome 
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inhibitor to date, whose cytotoxic effects may directly result from splicing inhibition. We posit 
that meayamycin B is a useful chemical probe to further validate the spliceosome as an 
anticancer target, and a starting point for development of novel antineoplastic agents. 
2.1.4 Experimental 
Preparation of compound solutions. All small molecules tested were dissolved in DMSO as 
stock solutions (10 mM) and stored at -20 °C. For the experiments, diluted solutions were 
prepared in DMSO immediately before use. Unless mentioned otherwise, stock solutions (1.0 
µL) at appropriate concentrations were directly added into cell culture media (200 µL) to afford a 
final 0.5% (v/v) DMSO concentration. This vehicle concentration was previously demonstrated 
to be nontoxic for the cells.129  
Cell Culture. The transformed HEK293 cell lines were gifts from Professor Melissa 
Moore (University of Massachusetts Medical School). The cells were cultured in Dulbecco’s 
Modified Eagle Medium supplemented with 10% (v/v) fetal bovine serum, 4.5 g/L D-glucose, 
2.0 mM L-glutamine, 100 units mL-1 penicillin and 100 µg/mL streptomycin. The cells were all 
maintained at 37 °C in a humidified atmosphere containing 5% carbon dioxide. Once the cells 
reached 70–80% confluency, they were either subcultured by being diluted at 1:10 to a new flask 
or used for experiments. Cells were discarded after 20 passages. 
Luciferase assay. Luciferase activity was evaluated by measuring the intensity of 
luminescence produced from luciferin oxidation using luciferase assay system kit (Promega). For 
the luciferase assay performed in a 96-well format, culture medium was removed by aspiration, 
and cells were rinsed once with phosphate-buffered saline (200 µL, 137 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4, and 2 mM KH2PO4). 1x Cell Culture Lysis Reagent (25 mM Tris-phosphate 
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pH 7.8, 2 mM DTT, 2 mM 1,2-diaminocyclohexane-N,N,N’,N’-tetraacetic acid, 10% (v/v) 
glycerol, 1% (v/v) Triton X-100; 20 µL) was then added to release the luciferase from the cells. 
After 10 min of incubation at 25 °C, the luciferase assay reagent (100 µL) (reconstituted by 
combining the luciferin substrate and luciferase assay buffer provided in the Promega Luciferase 
Assay Kit) was added to each well. Luminescence was measured immediately on a Spectromax 
M5 plate reader (Molecular Devices) or a Modulus II Microplate Multimode Reader (Turner 
BioSystems). With the M5 plate reader, white 96-well plates with clear bottoms were used. With 
the Modulus II, white solid-bottomed 96-well plates were used. 
BCA total protein assay. For luciferase assays (in a 96-well format) with which BCA 
protein assays were performed simultaneously in the same samples, Cell Culture Lysis Reagent 
(25 µL) was added to each well of cells. Aliquots (5 µL) of cell lysate from each well were 
transferred to a clear 96-well microtiter plate. Another 1x Cell Culture Lysis Reagent (20 µL) 
was then added to each aliquot (5 µL) to make a total volume of 25 µL, which was subsequently 
combined with the BCA assay reagent (200 µL). The samples were incubated at 37 °C for 30 
min before absorbance at 562 nm was measured. The total protein concentration (proportional to 
the absorbance at 562 nm) from each sample was measured based on a standard curve developed 
with pure BSA. The standard curve was obtained by diluting BSA by the same Cell Culture 
Lysis Reagent, and the dose-dependent increasing absorbance at 562 nm was then collected and 
fit into a built-in linear regression model in GraphPad Prism. 
Cell proliferation assay. Cell proliferation was evaluated using the MTS dye reduction 
assay with PMS as the electron acceptor assay performed in triplicate. To this end, cells were 
seeded in 96-well plates at 1.6×104 cells per well and incubated for 24 h at 37 °C. Cells were 
then exposed to various concentrations (serial three-fold dilutions) of the indicated compounds 
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for 72 h at 37 °C. An MTS solution (20 µL of MTS: PMS at 20:1) was added, and cells were 
incubated for 2 h at 37 °C before the absorption signals were measured at 490 and 650 nm. 
Growth inhibition was calculated as defined by the National Cancer Institute [GI50 = 100 × (T-
T0)/(C-T0); T0 = cell density at time zero; T = cell density of the test well after period of 
exposure to test compound; C = cell density of the vehicle treated]. 
Optimization of the length of exposure. To optimize length of exposure to meayamycin 
B, the HEK293-II cells were plated at 1.0×104 cells per well in 96-well white solid-bottomed 
polystyrene microplates and were incubated for 24 h. The cells were then subjected to 10 nM 
meayamycin B or DMSO (0.5 % v/v) as a vehicle control in duplicates for 3 d, and luciferase 
activity was measured at the indicated time points with a luciferase assay system (Promega). 
Data analysis and graphing were performed by using a GraphPad Prism software, version 5.0a 
for Mac OS X. 
Optimization of cell density. For a 16-h assay in a 96-well format, HEK293-II cells 
were seeded at 4.0×103–2.0×104 cells per well in duplicates with a 2.0×103 cell increment per 
well. After 40 h (mimicking 24 h cell-seeding plus 16 h compound treatment) of incubation, 
luciferase activity was measured.  
Evaluation of meayamycin B as a positive control. HEK293-II cells were plated at 
1.6×104 cells per well in 96-well plates and cultured for 24 h. Thereafter, cells were exposed in 
duplicates to either meayamycin B at various concentrations or DMSO for 16 h before luciferase 
activity was assessed. We subsequently calculated the ED50 value of splicing inhibition by 
meayamycin B to HEK293-II by plotting dose-response curves using a nonlinear regression 
model in GraphPad Prism. A BCA protein assay was adopted as an evaluation of cell density for 
each well that was measured for luciferase activity.  Each experiment was repeated on three 
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separate days to confirm the reproducibility, and the luciferase assay and BCA assay were 
carried out simultaneously. 
Z-factor. The HEK293-II cells were seeded at 1.6×104 per well in a white 96-well plate. 
After 24 h of incubation, 48 wells were treated with 10 nM meayamycin B for 16 h and the other 
48 wells were treated with DMSO. This experiment was repeated on three separate days. Dosing 
solutions were added manually with an Eppendorf Research® Plus pipette carrying 0.1–2.5 µL 
adjustable range of volumes. The random error limits of this pipette are ±6.0% (±0.075 µL) when 
a volume of 1 µL is delivered. Our calculated Z-factor values did not factor in these potential 
errors. The Z-factor was calculated using the equation shown below.140 σ and µ stand for 
standard deviation and mean, respectively; P and N stand for positive and negative controls, 
respectively.  
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RT−PCR. Cells were seeded at 3.5×105 per dish in 35-mm dishes for 24 h and were 
treated with DMSO or compounds dissolved in DMSO for 16 h. After aspirating the media, the 
total RNA was extracted with TRIzol® (Invitrogen). The RNA was dissolved in 
diethylpyrocarbonate-treated water and quantified in a UV-compatible 96-well plate by a 
Modulus II Microplate Multimode Reader at wavelengths of 260 and 280 nm (Abs260/Abs280). 
The RNA was free of degradation as determined by gel electrophoresis. Reverse transcription 
was carried out by using 200 U SuperScript® III reverse transcriptase (Invitrogen), each primer 
(2 pmol), ribonucleotide (10 nM each), 0.1 µM DTT, and RNAse inhibitor (20 U) for total RNA 
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(1 µg). The reaction conditions were as follows: 65 °C for 5 min, 0 °C for 1 min, 55 °C for 45 
min, and 70 °C for 15 min. Afterwards, the reaction mixture (2 µL) was used as the template for 
PCRs. The PCR program involves the initial denaturation at 94 °C for 5 min, 30 cycles at 94 °C 
for 30 s, 55 °C for 45 s, 72 °C for 45 s, and final elongation at 72 °C for 7 min. The primers for 
TPI minigene were EX1F 5’−TAA ACT TAA GCT TCA GCG CCT CGG−3’ and EX2R 
5’−TAG CGC TTC ATG GCT TTG TGC AG−3’; the primers for luciferase gene were Luc_F 
5’− TCA AAG AGG CGA ACT GTG TG−3’ and Luc_R 5’−GGT GTT GGA GCA AGA TGG 
AT−3’. PCR products and a MassRuler DNA ladder (MBI Fermentus) were resolved on 1.5% 
(w/v) agarose gels. The DNA in the gels stained with ethidium bromide was visualized by a UV-
Vis digital camera system (Eagle Eye II, Stratagene).  
Preparation of spliceostatin A. Spliceostatin A was prepared from FR901464 in our 
laboratory according to the literature.92 There is a lack of evidence for the purity of spliceostatin 
A in the original literature92 or any other published work involving the use of this agent. Multiple 
rounds of HPLC purification yielded ~90% pure spliceostatin A. 
Correlation assay. HEK293-II cells were treated with meayamycin B or herboxidiene at 
various concentrations and assayed under optimized screening conditions as described above. 
Cells for antiproliferation assays were treated simultaneously in the same manner. The 
antiproliferation was evaluated with the standard MTS method described above. Correlation 
analyses between luminescence intensity and relative viability data were performed using 
GraphPad Prism that calculated the Pearson’s correlation coefficient (r).144  
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2.2 MEAYAMYCIN B SENSITIZES NON-SMALL CELL LUNG CARCINOMA TO 
BCL-XL/BCL-2 INHIBITOR 
This section is in part taken from “Gao, Y. and Koide, K. (2013) Chemical perturbation of Mcl-1 
pre-mRNA splicing to induce apoptosis in cancer cells, ACS Chem. Biol. 8, 895–900.” 
2.2.1 Research design 
In this study, we aim to investigate the feasibility of manipulating anti-apoptotic Bcl-2 family 
members by small-molecule SF3b modulators, to the end of triggering apoptosis in cancer cells. 
The rationale is that many Bcl-2 family genes undergo alternative pre-mRNA splicing and 
produce both proapoptotic and antiapoptotic protein isoforms. For example, BCL2L1 and 
myeloid cell leukemia-1 (MCL1) genes are alternatively spliced into proapoptotic Bcl-xS and 
Mcl-1S, antiapoptotic Bcl-xL and Mcl-1L, and the unannotated Mcl-1ES, respectively.145-147 In 
cancer, antiapoptotic isoforms are predominant.148 Although other antiapoptotic Bcl-2 family 
proteins such as Bcl-2 and Bcl-w are present in cancer cells, inhibition of both Bcl-xL and Mcl-1L 
is necessary and sufficient to trigger massive cell death.149 In support of this notion, ABT-737 
(Figure 2-9), a small molecule that selectively binds to and antagonizes Bcl-2, Bcl-xL and Bcl-w, 
but not Mcl-1L,150-151 encountered resistance in cancer cells that overexpressed Mcl-1L.152-156 To 
circumvent the drug resistance, Mcl-1 expression was inhibited by biological or pharmacological 
means, which restored the anticancer activity of ABT-737.152, 157-158 However, the only endeavor 
successfully sequestering Mcl-1L by perturbing the alternative splicing of Mcl-1 pre-mRNA was 
antisense morpholino oligonucleotides.159 So far, there is no small molecule reported to have 
such activity. 
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The expression of Mcl-1S and Bcl-xS mRNAs was upregulated when splicing factor 3B 1 
(SF3B1; a.k.a. SAP155) was knocked down, indicating that SF3B1 is involved in the alternative 
splicing of these apoptosis-related genes.123 SF3B1 has also been identified as a trans-acting 
splicing factor that enhances the production of Bcl-xL in A549 cells.64 Having demonstrated that 
meayamycin B (Figure 2-9) as the most potent SF3B1 inhibitor,160 here, we hypothesized that 
meayamycin B could switch the alternative splicing of Bcl-x and/or Mcl-1 pre-mRNAs towards 
the overexpression of Bcl-xS and Mcl-1S, which might overcome ABT-737 resistance. We 
choose non-small cell lung carcinoma (NSCLC) because they commonly overexpress anti-
apoptotic Bcl-2 proteins.161  
 
Figure 2-9 Structures of meayamycin B and ABT-737 
 
2.2.2 Results and Discussion 
2.2.2.1 Dose-dependent modulation of alternative splicing of Mcl-1  
Mcl-1L is generally overexpressed in non-small cell lung cancer cells including A549 and H1299 
cells.162-163 To test the aforementioned hypothesis about meayamycin B, A549 and H1299 cell 
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lines were exposed to meayamycin B at various concentrations. The exposure time was only 9 h, 
which was sufficient to generate clear-cut data because the half-life of Mcl-1 mRNA is 
approximately 40 min.164-165 The short assay also minimizes the downstream secondary effects of 
meayamycin B. After the 9-h exposure, the relative mRNA levels of Mcl-1 splicing variants 
including Mcl-1L and Mcl-1S were evaluated by means of semi-quantitative RT-PCR (Figure 2-
10A). For the RT-PCR experiment, we used primers (see Table 2-1 and arrows in Figure 2-10A) 
that were designed to reverse-transcribe multiple sites of the gene. As shown in Figure 2-10B, 
meayamycin B dose-dependently downregulated and upregulated Mcl-1L and Mcl-1S, 
respectively (NCBI GenBank accession number NM_021960 and NM_182763).146 Specially, the 
ratio of Mcl-1S/Mcl-1L increased from 0.0065 (H1299 cells) and 0.035 (A549 cells) with DMSO 
to 69 (H1299 cells) and 5.9 (A549 cells) with 100 nM meayamycin B. In accordance with the 
change at the mRNA level, immunoblotting showed that meayamycin B abrogated the 
expression of the full length Mcl-1 protein isomer Mcl-1L (40 kDa) and simultaneously increased 
Mcl-1S (35 kDa) (Figure 2-10C). Mcl-1L protein was more prevalent in H1299 than in A549, 
which might explain why 10 nM meayamycin B was required to completely remove Mcl-1L in 
H1299 cells. Mcl-1S protein became the dominant Mcl-1 isoform in A549 cells with only 0.1 nM 
meayamycin B. 
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Figure 2-10 Dose-dependent regulation of Mcl-1 alternative splicing 
 
2.2.2.2 Time-dependent modulation of alternative splicing of Mcl-1 
Mcl-1 has a very short half-life at the mRNA and protein levels.164-165 Therefore, we thought it 
would be possible to observe changes in the expression of MCL1 soon after the addition of 
meayamycin B to the aforementioned cells. Thus, H1299 and A549 cells were exposed to 10 nM 
meayamycin B for 1, 3, 9, and 24 h before relative expression of Mcl-1 splicing variants were 
determined at the mRNA and protein levels. The semi-quantitative RT-PCR analysis revealed 
that the increase of the Mcl-1S mRNA was detectable after 1 h of treatment (Figure 2-11A). In 
addition, the suppression of the Mcl-1L mRNA by meayamycin B was complete in 9 h and 
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remained as such for the next 15 h. At the protein level (Figure 2-11B), Mcl-1S was the dominant 
Mcl-1 isoform in both A549 and H1299 cell lines after 9 h of exposure to meayamycin B. 
 
Figure 2-11 Time-dependent regulation of Mcl-1 alternative splicing 
 
We also observed larger RT-PCR products that increased over time. These products were 
partially spliced Mcl-1 pre-mRNA retaining both intron 1 and intron 2 (Figure 2-12), indicating 
that meayamycin B acted as both a constitutive splicing inhibitor and an alternative splicing 
modulator for Mcl-1 pre-mRNA.  
Of note, we did not detect the full-length pre-mRNA in the cytoplasm of the cells 
exposed to meayamycin B. This is consistent with the recent evidence showing SF3B1 inhibition 
can affect mRNA surveillance NMD pathways, causing the leakage of partially spliced pre-
mRNA into cytoplasm for translation. In addition, full-length pre-mRNA could not be efficiently 
exported in to cytoplasm since this species was absent in the RT-PCR products.100  
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Figure 2-12 Meayamycin B inhibits the constitutive splicing of Mcl-1 
 
2.2.2.3 Meayamycin B does not regulate alternative splicing of Bcl-x 
SF3B1 is also a trans-acting splicing factor for the Bcl-x gene in A549 cells.64 In neither dose- 
nor time-dependent treatments did meayamycin B significantly increase Bcl-xS (Figure 2-12). 
This is in agreement with the results from the Webb group using sudemycins (analogs of 
FR901464) in pediatric rhabdomyosarcoma cell line Rh18 for 24 h.81 We reasoned that since 
SF3B1 might regulate Bcl-xL alternative splicing only in response to ceramide. Interestingly, 
RNAi knockdown of SF3B1 resulted in alteration of the alternative splicing of both Mcl-1 and 
Bcl-x. In our model system, the different responses between the Mcl-1 system and the Bcl-x 
system toward meayamycin B indicate the complexity of the regulatory pathways of these two 
anti-apoptotic Bcl-2 proteins. Besides, the effect of RNAi and small-molecule inhibitor again 
protein targets could be strikingly different when the target proteins are heavily involved in 
protein-protein and protein-RNA/DNA interactions.166 SF3B1 fits in this category of protein 
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targets. While biological means eliminates physical SF3B1, which might inevitably affects the 
actions of all binding partners of SF3B1, chemical approach such as meayamycin B disables 
SF3B1, whose physical scaffold might still serve its due functions that rely on interactions with 
other proteins and RNA molecules. Given the fact that there is no proof showing that SF3B1 
directly binds to a cis-regulatory element on Mcl-1 pre-mRNA, like CRCE-1 on Bcl-x in 
response to ceramide, this incongruent observation about Bcl-x alternative splicing calls for 
further investigation of the role of SF3b (possibly SF3B1) at global alternative splicing level. 
2.2.2.4 Meayamycin B sensitizes A549 and H1299 cells to ABT-737 
Mcl-1L expression has been recognized as the culprit for ABT-737 resistance in various cancers, 
including lung cancer cell monolayer cultures and spheroids.154, 157, 167 Therefore, we 
hypothesized that meayamycin B could overcome the ABT-737 resistance in cancer cells that 
rely on Mcl-1L to survive. To test this hypothesis, A549 and H1299 cells were exposed to serial 
dilutions of meayamycin B and ABT-737 as single agents or in simultaneous combination at a 
constant ratio (meayamycin B:ABT-737 = 1:500) based on the Chou and Talalay method for 72 
h.168 Post-treatment cell viability was evaluated using 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) method. ABT-737 
did not affect cell viability as a single agent even at a 100 µM concentration that is the upper 
limit due to its solubility in a cell culture medium (Figure 2-13A and B). Meayamycin B 
inhibited cell growth as a single agent with GI50 values of 0.14 ± 0.008 nM and 0.15 ± 0.008 nM 
(n = 3) in A549 and H1299 cells, respectively. With meayamycin B by itself, the treated cells did 
not undergo cell death. In sharp contrast, a combination of meayamycin B and ABT-737 induced 
cell death at doses (≥ 10 nM and ≥ 2.5 µM, respectively) that were not cytotoxic with either of 
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the two compounds as single agents. When the treated cells were examined under a microscope, 
only the combination treatment caused apoptosis-like cell shrinkage (data not shown). Although 
full cell-killing curves from each compound as a single agent could not be generated due to the 
poor solubility of ABT-737, preventing us from calculating the combination index values,168 the 
remarkable cytotoxic effect from the meayamycin B–ABT-737 combination indicated a strong 
synergism. Interestingly, under a microscope, H1299 cells displayed more prominent apoptotic 
morphology than A549 cells upon meayamycin B treatment. This might be related to the 
different p53 gene status: A549 expresses wild-type p53 protein while H1299 is p53-deficient.169 
Further studies are warranted since generally the p53-null genotype in H1299 affords them 
stronger resistance to apoptotic stimuli.170 Nonetheless, the sensitivity of H1299 cells indicated 
that the apoptosis triggered by the combination of meayamycin B and ABT-737 does not require 
the expression of wild-type p53. 
2.2.2.5 Mcl-1 abundance correlates with meayamycin B-sensitivity   
After examining the potency of meayamycin B in H1299 and A549, we used immunoblotting to 
assess the basal expression of antiapoptotic Bcl-2 family proteins in these cell lines. It was 
demonstrated that H1299, expressing higher level of Mcl-1L, was also more responsive to single-
agent meayamycin B. The basal Mcl-1L level (Mcl-1L/β-actin) was 1.32 in H1299 versus 0.41 in 
A549 (Figure 2-13C) and meayamycin B dropped the cell viability to approximately 50% and 
75% in H1299 and A549, respectively. The same pattern was also observed in head-and-neck 
squamous cell carcinoma (HNSCC) cell lines. As an example, the data from PCI-13 and 93-UV-
147T showed Mcl-1L expression levels at 1.24 and 0.07 (Figure 2-13D). In consistence, 
meayamycin B reduced the cell viability to 0% in PCI-13 but was inactive in 93-UV-147T 
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(Figure 2-13E and 2-13F). These data indicate the potential use of meayamycin B for cancer 
types that overexpress Mcl-1L. 
 
Figure 2-13 Mcl-1 abundance correlates with meayamycin B-sensitivity 
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2.2.2.6 Meayamycin B and ABT-737 combination synergistically causes apoptosis  
To determine whether the combination induced apoptosis, we measured the caspase 3/7 activity 
of the treated H1299 and A549 cells. The cells were exposed to the combination of meayamycin 
B and ABT-737, as single agent or in combination, at 1 nM and 500 nM (their GI50 values when 
used in combination), respectively. After 9 h exposure, although single-agent ABT-737 caused 
an increase of caspase 3/7 activity in a dose-dependent manner, the combination treatment 
induced a significantly higher level of caspase 3/7 activity (Figure 2-14). The major cell death in 
24-h combination treatment led to a relatively low caspase 3/7 readout. Meayamycin B by itself 
was a weak apoptosis inducer. The rapid activation of caspase 3/7 observed in the combination-
treated cells indicated a strong synergism between meayamycin B and ABT-737 in inducing 
apoptosis.  
 
Figure 2-14 Rapid onset of apoptosis triggered by the combination in NSCLC cells 
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To better understand the stages of apoptosis in the cells exposed to the combination of 
meayamycin B and ABT-737, we stained the cells with fluorescein isothiocyanate (FITC), 
annexin V, and 7-aminoactinomycin D (7-AAD) and monitored the fluorescence with flow 
cytometry. Annexin-V stains early apoptotic cells by detecting the externalization of 
phosphatidylserine,171 and 7-AAD intercalates double-stranded DNA to detect dead or late-stage 
apoptotic cells.172 The cells treated with both meayamycin B and ABT-737 displayed a 
significantly higher population of annexin V+/7-AAD–, indicating that these cells were in an 
early stage of apoptosis (Figure 2-15, lower right quadrants) and annexin V+/7-AAD+ (late 
apoptotic/necrotic; Figure 2-15 upper right quadrants), indicating synergistic apoptosis 
stimulation.  
 
Figure 2-15 Apoptosis activation monitored with Annexin V-FITC and PI staining 
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2.2.3 Conclusion 
In conclusion, meayamycin B inhibits the constitutive splicing and switches the alternative 
splicing of Mcl-1 in a dose- and time-dependent manner in non-small cell lung cancer A549 and 
H1299 cell lines. The alteration of Mcl-1 alternative splicing increased pro-apoptotic Mcl-1S 
with a concomitant decrease of anti-apoptotic Mcl-1L. This is, to the best of our knowledge, the 
first report of the modulation of Mcl-1 alternative splicing by a single small molecule. Although 
both A549 and A1299 cells were resistant to cell death in the presence of either meayamycin B 
or ABT-737, treatment of these cells with both meayamycin B and ABT-737 induced cell death, 
presumably through the meayamycin B-mediated modulation of Mcl-1 pre-mRNA splicing. 
These results support the feasibility of using the combinations of Mcl-1L and Bcl-xL inhibitors 
for both research and therapeutic purposes. 
2.2.4 Experimental 
Cell lines. A549 and H1299 cells were obtained from the American Type Culture Collection 
(ATCC). PCI-13 and 93-UV-147T cell lines are kind gifts from Dr. Robert Ferris (University of 
Pittsburgh). The A549 and H1299 cells were maintained in Roswell Park Memorial Institute-
1640 (RPMI-1640) medium, PCI-13 were grown in Dulbecco's Modified Eagle's Medium and 
93-VU-147T cell line was grown in DMEM/F12 medium. All media were supplemented with 
10% (v/v) fetal bovine serum, 4.5 g/L D-glucose, 2.0 mM L-glutamine, 100 units/mL penicillin, 
and 100 µg/mL streptomycin.  The cells were cultured at 37 °C in a humidified incubator with 
5% CO2.  
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Compound treatment. ABT-737 was purchased from Selleck. Meayamycin B was 
synthesized in our laboratory.94 The compounds were dissolved in dimethyl sulfoxide (DMSO) 
to make 10 mM stock solutions and stored at –20 °C. For 96-well format assays, we diluted the 
compounds with cell culture medium and transferred each dilution (100 µL) to cell cultures (100 
µL) in triplicate. For 35-mm dish-format assays, cells were seeded in 35-mm dishes and cultured 
for 24 h (~70% confluence) before vehicle or test compounds were added directly from stock at 
appropriate concentrations. In both cases, the final vehicle% was controlled at 0.5% for all of the 
treatments. After incubation for the indicated periods of time (1, 3, 9 and 24 h for time-
dependence experiments, 9 or 72 h for dose-dependence experiments), the cells in 96-well plates 
were lysed and subjected to luciferase assays or caspase-3/7 assays and the cells from 35-mm 
dishes were subjected to total RNA extraction and the RT-PCR experiments. 
Apoptosis detection: (1) FITC Annexin V and 7-aminoactinomycin D (7-AAD) staining. 
Cells (1 x 106 cells) were treated for 9 h with 10 nM meayamycin B, 5 µM ABT-737, a 
combination of these compounds, or an equal volume of DMSO as a negative control. After 
treatment, the cells were harvested, washed in ice-cold PBS, and directly stained with 5 µg mL–1 
FITC Annexin V (BD Pharmingen, cat. no. 556420) and 2.5 µg mL–1 7-AAD (BD Pharmingen, 
cat. no. 559925). After 20 min of incubation at room temperature in the dark, cells were analyzed 
by flow cytometry using a Beckman Coulter Epics XL-MCL. Data were analyzed using Summit 
V4.3 software. (2) Caspase 3/7 activity assays. The cells were seeded at 10,000 well–1 in medium 
(100 µL) in white solid-bottom 96-well plates and cultured for 24 h. Meayamycin B (0.1, 1, 10 
and 100 nM) and ABT-737 (0.05, 0.5, 5 and 50 µM), either separately or in combination 
(constant ratio of 1:500), were added in duplicate into the cells for 9 h. Caspase-3/7 activity was 
quantified using a Caspase-Glo® 3/7 reagent (Promega, cat. no. G8091) following the 
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manufacturer’s optimized protocol. Specifically, the Caspase-Glo® 3/7 buffer and the substrate 
were equilibrated to room temperature and mixed immediately before assays. This conjugated 
assay buffer (100 µL) was added to a cell culture (100 µL) that was equilibrated to room 
temperature and the mixture was incubated at room temperature for 1 h. Luminescence was 
directly measured with a Modulus II Microplate Multimode Reader. The caspase-3/7 activity 
was expressed as the mean luminescence of compound-treated wells divided by that of vehicle-
treated wells.  
Semi-quantitative reverse transcription-Polymerase Chain Reaction (RT-PCR). The 
total RNA was extracted using a Trizol reagent (Invitrogen, cat. no. 15596-026) and cDNA 
generated by reverse transcription using 1 µg of total RNA and SuperScript® II reverse 
transcriptase (Invitrogen, cat. no. 18064-014). The primer sequences are shown in Table 2-1. For 
semi-quantitative RT-PCR, the thermocycler program for Bcl-x, Mcl-1 and β-actin involved an 
initial denaturation at 94 °C for 5 min, 35 cycles at 94 °C for 30 sec, 58 °C for 30 sec, 72 °C for 
50 sec, and a final elongation at 72 °C for 7 min. The PCR products were examined on 1.5% 
agarose gels containing 0.5 µg/mL ethidium bromide and imaged by a Molecular Imager Gel 
Doc XR+ (BioRad). The intensity of the bands was quantified with the Lab Imager software 
(BioRad). 
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Table 2-1 Primer sequences for RT-PCR experiments in NSCLC system 
Genes Sequences 
Bcl-x 
Bcl-xF: 5’- GAG GCA GGC GAC GAG TTT GAA -3’ 
Bcl-xR: 5’- TGG GAG TTG AGA GTG GAT GGT -3’ 
Mcl-1 
Mcl-1F: 5’- ATC TCT CGG TAC CTT CGG GAG C -3’ 
Mcl-1R: 5’- CCT GAT GCC ACC TTC TAG GTC C -3’ 
Mcl-2F: 5’- AGG AAT TCG ATG TTT GGC CTC AAA AGA AAC GCG GTA -3’ 
Mcl-2R: 5’- GAA TTC GGA AGT TAC AGC TTG GAG GAG TCC AAC TGC -3’ 
β-actin 
Forward: 5’- GCA CCA CAC CTT CTA CAT GAG C -3’ 
Reverse: 5’- TAG CAC AGC CTG GAT AGC AAC G -3’ 
 
Western blotting. Cells were harvested in a cell lysis buffer (50 mM Tris-HCl, 150 mM 
NaCl, 1% Triton X-100, 0.1% SDS, and 1 mM PMSF) and a mixture of protease inhibitors 
(Roche, cat. no. 05 892 791 001). Total protein (100 µg) was electrophoresed on a 12% SDS-
polyacrylamide gel and electrotransferred to a polyvinylidene difluoride membrane (Millipore, 
cat. no. IPVH10100). Membranes were blocked at room temperature for 1 h with a blocking 
buffer (5% non-fat dry milk in 10 mM Tris-HCl pH7.6, 150 mM NaCl, 0.1% Tween-20) and 
then incubated at 4 °C overnight with rabbit anti-Mcl-1 monoclonal antibody (1:1000 dilution; 
Cell signaling technology, cat. no. 5453S), rabbit anti-Bcl-xL/S monoclonal antibody (1:1000 
dilution; Santa Cruz, cat. no. sc-634) or rabbit anti-β-actin monoclonal antibody (1:1000 
dilution; Cell signaling technology, cat. no. 4970S), followed by 1 h of incubation with 
horseradish peroxidase-conjugated anti-rabbit (1:1000 dilution; Cell signaling technology, cat. 
no. 7074S) secondary antibody. Blots were developed with ECL Plus reagents (PerkinElmer Life 
and Analytical Science, cat. no. NEL103001EA). Mcl-1L, Mcl-1S, Bcl-xL, Bcl-xS, and β-actin 
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proteins migrated at 40, 35, 30, 26, and 45 kDa, respectively. The densities of the resulting bands 
were quantified using Image Gauge Ver. 4.0 (FUJIFILM). 
Statistics. Data analysis and graph plotting were carried out using a GraphPad Prism 5.0c 
for Mac (GraphPad Software). All the data were presented as mean ± standard deviation. The 
significance level for all analyses was 5%. 
2.3 MEAYAMYICN B SENSITIZES HEAD AND NECK SQUAMOUS CELL 
CARCINOMA TO BCL-XL/BCL-2 INHIBITOR 
This section is in part taken from the manuscript entitled “Gao, Y., Trivedi, S., Ferris, R., and 
Koide, K. SF3B1 inhibitor perturbs the splicing of HPV16 E6 and MCL1 and synergistically 
induces apoptosis in combination with a BCL-XL/BCL-2 inhibitor in head and neck squamous 
cell carcinoma”. 
2.3.1 Introduction 
HNSCC is the sixth most common cancer worldwide.173 HNSCC mostly occurs by 
cigarette/alcohol consumption; however, a subgroup of HNSCC (26%) is caused by the 
integration of high-risk human papillomavirus (HPV), especially HPV16.174 It has been 
perplexing that only ~10% of those who were exposed to high-risk HPV16 or 18 develop 
cancer.175 In oropharyngeal carcinoma particularly, HPV16 is detected in over 60% of the cancer 
tissues.176 Due to their distinct mechanisms of tumorigenesis, HPV-positive and HPV-negative 
HNSCC should be treated separately.177-178 Platinum-based chemotherapy, the most commonly 
 59 
used drug regardless of HPV status, is far less effective against HPV-negative HNSCC.179-180 
Moreover, in the past thirty years, the five-year overall survival rate of HNSCC has not 
improved,181 warranting the discovery of new pharmacological interventions. 
The discovery of novel therapeutics requires a comprehensive understanding of the 
disease biology. Since HPV16 is present in nearly 60% of all cervical cancers,182 its expression is 
most widely studied in cervical cancer models. The HPV16 genome encodes six early (E) viral 
proteins (E1, E2, E4, E5, E6, and E7) and two late (L) viral capsid proteins (L1 and L2), 
accompanying the differentiation stages of the host keratinocytes.183 Among these proteins, only 
the overexpression of E6 and E7 was correlated with malignant transformation.184 At the 
transcription level, E6 and E7 share a mutual early p97 promoter. Because the open reading 
frames of E6 and E7 are only 2 nucleotides apart, the transcription of full-length E6 prohibits the 
translation of E7 protein. Otherwise, when intron 1 (Figure 2-16) is excised, splicing variant E6* 
is generated, which in turn allows the translation of E7.185-186 In response to epidermal growth 
factor (EGF), the activation of ERK1/2 pathway facilitates the production of E6. SiRNA 
knockdown experiments demonstrated that hnRNP A1 and hnRNP A2/B1 favored E6, while 
splicing factor Sam68 and transcription factor Brm favored E6*.187 This report indicated that 
splicing and transcription are coupled in HPV16 E6/E7 expression. 
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Figure 2-16 Generation of HPV16 E6 and E7 oncoproteins 
 
Functionally, E6 inhibits apoptosis by triggering the degradation of p53, and E7 enhances 
cell proliferation by binding to another tumor suppressor protein retinoblastoma-associated 
protein (pRb).188-189 Whereas the function of full-length E6 is relatively well understood, the 
function of E6* is still elusive, and available data lend controversial conclusions; through RT-
PCR analysis, E6* expression was found to be significantly higher in late stage cervical lesion 
than early stage counterparts.190-191 In contrast, E6* counteract the anti-apoptotic action of E6 in 
the degradation of p53 and precaspase 8.192-193 Additionally, the overexpression of E6* is 
cytotoxic when expressed in immortalized monkey fibroblasts CV-1 cells.194 In sum, these 
unconnected pieces of data argue that both basic and translational studies of E6 splicing are 
lagging behind, calling for further studies advanced by novel strategies. 
Meayamycin B (Figure 2-9), the most potent inhibitor of SF3b, sensitized NSCLC cells 
(A549 and H1299) to ABT-737 (Figure 2-9) by modulating the splicing of Mcl-1.195 Similar 
observations were reported for the combination of spliceostatin A (structurally similar to 
meayamycin B) and ABT-737 in neuroblastoma.196 Given the mutual risk factors, such as 
alcohol and cigarette consumption, shared between NSCLC and HNSCC,197-198 we reasoned that 
meayamycin B might also prime HNSCC cells for ABT-737. Therefore, we wished to examine 
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the anticancer activity of meayamycin B, as a single-agent or in combination with ABT-737. In 
addition, we used meayamycin B to examine the role that SF3B1 plays in the splicing of Mcl-1 
and more importantly, HPV16 E6.  
2.3.2 Results and Discussion 
2.3.2.1 Meayamycin B and ABT-737 combination causes apoptosis 
We investigated the apoptotic response of a panel of HNSCC cells to meayamycin B and ABT-
737. There are two methods in common use for calculating the dose-response relationship 
expected from combination therapy when two drugs are assumed to have no interactions: Loewe 
additivity199 and Bliss independence.200 Loewe additivity assumes that two inhibitors act on a 
target through a similar mechanism, as shown by Chou and Talalay for mutually exclusive 
enzyme inhibitors.168 Bliss independence assumes that inhibitors can bind mutually and 
nonexclusively through distinct mechanisms. Unfortunately, the insufficient water solubility of 
ABT-737 prohibited the generation of dose response curves required for the Loewe method. 
Therefore, Bliss independence was used to determine drug interactions. To this end, we 
performed 72-h MTS-based antiproliferation assays in a panel of seven cell lines including PCI-
13, PCI-15B, UM-SCC22B, UPCI:SCC90, 93-VU-147T, UM-SCC47, and UD-SCC2. The GI50 
values (n = 3) are shown in Table 2-2.  
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Table 2-2 GI50 values for 72-h antiproliferation assays in HNSCC cells  
Cell lines 
GI50 
Single agent ABT-737 (µM) in 
combination Meayamycin B (nM) ABT-737 (µ M) 
PCI-13 
HPV16-negative 
0.19±0.07 15±1.8 0.59±0.83 
PCI-15B 0.14±0.06 11±4.5 0.19±0.19 
UM-SCC22B 0.60±0.12 19±2.9 0.84±0.86 
UM-SCC47 
HPV16-positive 
0.038±0.006 19±12.3 0.20±0.11 
93-VU-147T 0.074±0.039 4.3±3.5 0.50±0.70 
UD-SCC2 0.025±0.009 28±2.9 0.15±0.02 
UPCI:SCC90 0.074±0.022 6.6±1.5 0.14±0.082 
 
Meayamycin B only arrested the growth of 93-VU-147T, UM-SCC47, and UD-SCC2 
cells, while the combination of meayamycin B and ABT-737 eradicated these cells (Figure 2-
17). In the other four cell lines, especially UM-SCC22B and UPCI:SCC90, single-agent 
meayamycin B induced substantial cell death, nearly the same level caused by the combination 
with ABT-737.  
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Figure 2-17 Antiproliferation assays of meayamycin B and ABT-737 in HNSCC cells 
 
As an evaluation of drug interaction with Bliss independence, we calculated ΔE values 
for the combination treatment in each cell line. Assuming the two test compounds have additive 
interactions, ΔE is expressed as the difference between the expected and the observed cell 
viabilities. As shown in Figure 2-18A, the combination caused significantly higher levels of cell 
death than expected. Accordingly, Bliss sums clustered in the range of 400–600 (Figure 2-18B), 
indicating strong synergism. Meayamycin B dropped ABT-737’s GI50 values by 1–2 orders of 
magnitude. These data underscore the scope and generality of the efficacy from the combination 
of meayamycin B and ABT-737 in HNSCC cell lines. 
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Figure 2-18 Bliss Independence evaluation of meayamycin B and ABT-737 combination 
 
To confirm that the meayamycin B and ABT-737 combination causes apoptosis, we 
stained treated cells with Annexin V-FITC and PI and monitored the rates of apoptosis using 
flow cytometry. To demonstrate an early onset of apoptosis triggered by the combination, we 
chose 4-h exposure for four HNSCC cell lines (PCI-15B and PCI-13 as HPV16-negative, and 
UM-SCC47 and UPCI:SCC90 as HPV16-positive). After 4-h exposure, we observed 5–10% 
more Annexin V-positive population (Figure 2-19, right quadrants) in the combination-treated 
than in the cisplatin-treated (20 µg/mL, positive control) cells, indicating the rapid apoptosis by 
the combination. Necrosis (Figure 2-19, upper left quadrants) was also induced as a secondary 
event in the apoptotic pathway.201  
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Figure 2-19 Apoptosis activation monitored with Annexin V-FITC and PI staining 
 
As a downstream apoptotic event, caspase 3/7 (9-h exposure) experienced 7- to 15-fold 
increases almost exclusively in combination-treated cells (Figure 2-19A upper panel). Single-
agent ABT-7373 more strongly activated caspase 3/7 in HPV16 negative and UPCI:SCC90 cells. 
Meayamycin B, on the other hand, was not a strong apoptosis inducer. The combination also led 
to higher growth inhibition in HPV16 negative cell lines (Figure 2-19A lower panel). Taken 
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together, the Annexin V-FITC/PI staining and the caspase 3/7 activity assays both suggest rapid 
induction of synergistic apoptosis by the combination of meayamycin B and ABT-737. 
To determine whether the onset of apoptosis is mediated by Bax/Bak, we exposed Bax-/-
/Bak-/- mouse embryonic fibroblasts (MEFs) and SV40-immortalized wild-type MEFs to the 
combinations of meayamycin B and ABT-737. We chose 9-h exposure for caspase 3/7 activity 
assays because it should take more than 4 h to observe the downstream effects of meayamycin B. 
Similarly to HNSCC, the wild-type, but not Bax-/-/Bak-/- MEFs, showed dose-dependent caspase 
3/7-activation upon the combination treatments (Figure 2-20B upper panel). Accordingly, Bax-/-
/Bak-/- MEFs were significantly more resistant to the combination treatments (Figure 2-20B 
lower panel), suggesting that Bax/Bak-mediated apoptosis is a mechanism of cell killing by the 
combination of meayamycin B and ABT-737. Of note, other cell death pathways such as 
autophagy might have contributed to a ~15% decrease of proliferation in Bax-/-/Bak-/- MEFs 
caused by the combination, since Mcl-1-elimination triggers autophagic cell death when Bax is 
defected.201-202 This hypothesis needs to be tested through more experiments. 
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Figure 2-20 Bak/Bax-mediated apoptosis 
2.3.2.2 Basal level of MCL-1 correlates with meayamycin B sensitivity  
In PCI-13 and 93-VU-147T cells, we previously observed a correlation between the Mcl-1L level 
and the cellular response to meayamycin B.195 To determine whether basal Mcl-1L expression 
more broadly correlates with meayamycin B sensitivity, we assessed the basal expression of 
Mcl-1L, Bcl-x, and Bcl-2 using Western blotting (Figure 2-21). Mcl-1L was the dominant Mcl-1 
isoform in all the cell lines except UM-SCC22B, which exclusively expressed Mcl-1S. In 
addition, the total levels of Mcl-1 in PCI-13, PCI-15B, UM-SCC22B and UPCI:SCC90 were 
consistently higher than those in the other cell lines (Mcl-1/β-actin ≥ ~1.5 versus ≤ 0.8). 
Interestingly, three out of the four Mcl-1-abundant cell lines were HPV16-negative. Conversely, 
Bcl-XL was expressed in all the cell lines at levels statistically unrelated to meayamycin B 
response; Bcl-2 was only detected in UPCI:SCC90. 
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Figure 2-21 Basal expression of anti-apoptotic Bcl-2 proteins at the protein level 
In the meantime, the efficacy of meayamycin B against the seven HNSCC cell lines was 
revisited. Based on their responses to the compound, they fell into two sub-groups; PCI-13, PCI-
15B, UM-SCC22B and UPCI:SCC90 were nearly eradicated, while UM-SCC47, UD-SCC2, and 
93-VU-147T stopped growing upon meayamycin B exposure at sub- to low-nanomolar 
concentrations (Figure 2-22). With the exception of UPCI:SCC90, all meayamycin B-responsive 
cell lines were HPV16-negative, indicating that HPV16 might desensitize cells to meayamycin 
B. In summary, HPV16-negative, Mcl-1-abundant HNSCC cells were more responsive to 
meayamycin B. 
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Figure 2-22 Anti-proliferative activity of meayamycin B in HNSCC cell lines 
 
2.3.2.3 Regulation of the splicing of Mcl-1 pre-mRNA 
Mcl-1 pre-mRNA is spliced into antiapoptotic Mcl-1L (solid line; Figure 2-10A) and 
proapoptotic Mcl-1S (dotted line). We exposed the cells to meayamycin B either at 3 nM for 
various periods (1, 9, and 24 h) or for 9 h at various doses (0.03, 0.3, and 3 nM). At the mRNA 
level, meayamycin B up-regulated Mcl-1S and down-regulated Mcl-1L in a dose- and time-
dependent manner in all tested HNSCC cell lines (Figure 2-23A and B). This reciprocal change 
of the two isoforms was detectable at 9 h with 0.3 nM or 1 h with 3 nM meayamycin B 
treatments and peaked within 9 h of 3 nM meayamycin B exposure. Meayamycin B did not 
generate other splicing variants of MCL1 as evidenced by results from the RT-PCR for an 
amplicon (see Table 2-3 for sequences) spanning all three exons of MCL1.  
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Figure 2-23 RT-PCR analysis of the alteration of Mcl-1 alternative splicing 
 
At the protein level, we observed the same alteration of Mcl-1 splicing by meayamycin B 
in six of the seven HNSCC cell lines (Figure 2-24); in UM-SCC22B, RT-PCR showed a switch 
of Mcl-1 alternative splicing, but Western blotting showed only a dominant Mcl-1S regardless 
the meayamycin B exposure. This observation indicates that Mcl-1 expression may be regulated 
at other levels, such as post-translational modifications, that are specific for this cell line.  
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Figure 2-24 Western blotting analysis of the alteration of Mcl-1 alternative splicing 
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Also, in comparison to a partial obliteration of Mcl-1L caused by single-agent 
meayamycin B, the cells exposed to the combination for the same period (9 h in PCI-15B) 
completely lost both variants of Mcl-1, demonstrating the onset of apoptotic cell death (Figure 2-
25). 
 
Figure 2-25 Enhanced Mcl-1 elimination by meayamycin B and ABT-737 combination 
 
Meayamycin B also inhibited the constitutive splicing of Mcl-1 in UM-SCC22B, PCI-
15B, PCI-13, and UM-SCC47 cell lines, as manifested by the accumulation of transcripts 
without exon 1 (Figure 2-26) in cytoplasm. These are partially spliced pre-mRNA containing the 
two introns. This observation is consistent with previous report in other cancer cell models.100, 195 
The full-length pre-mRNA was not detected in any of these cell lines, indicating the incapability 
of this RNA species to be transported out of nucleus. 
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Figure 2-26 Meayamycin B inhibits constitutive splicing Mcl-1 
 
In parallel, we also examined BCL-X, which is also prone to regulation at the pre-mRNA 
splicing level in response to anticancer drugs, producing enhanced levels of the proapoptotic Bcl-
XS.203 As shown in Figure 2-27, the splicing of BCL-X did not change when the cells were 
incubated with 3 nM meayamycin B for up to 24 h, in agreement with our observation in 
NSCLC.195 
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Figure 2-27 Meayamycin B does not regulate Bcl-x alternative splicing 
2.3.2.4 Cell type-dependent inhibition of HPV-16 E6 splicing 
During the splicing process, inclusion or exclusion of intron 1 of E6 produces E6 or E6* splicing 
variant, respectively (Figure 2-16). We assessed the levels of E6 and E7 mRNA in meayamycin 
B- or DMSO-treated HPV16-positive HNSCC cell lines. Figures 2-28A and B show that the full-
length transcript was dominant for E6 in the DMSO-treated cells. In meayamycin B-treated UM-
SCC47, 93-VU-147T, and UPCI:SCC90 cells, E6 mRNA increased and E6* mRNA decreased 
in a dose- and time-dependent manner. The inhibition was observed as early as 1 h of 
meayamycin B-exposure as demonstrated in UPCI:SCC90 cells (Figure 2-28C). However, this 
alteration was not as prominent in cell lines constitutively expressing lower levels of E6*, such 
 75 
as UD-SCC2 cells. Due to the unavailability of HPV16 E6 antibody, we did not examine the 
changes of splicing of E6 at the protein level. In all HPV16-positive cell lines, the E7 mRNA 
level was unaffected, although E6 and E7 genes are co-transcribed.204 
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Figure 2-28 Meayamycin B regulates HPV16 E6/E7 splicing 
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2.3.2.5 SF3B1 inhibition by siRNA and meayamycin B  
Subsequently, we asked whether SF3B1 regulates the splicing of HPV16 E6 and Mcl-1. To 
answer this question, we decided to examine the splicing regulation of HPV16 E6 and Mcl-1 by 
SF3B1 knockdown and meayamycin B treatment, individually or in combination. Since none of 
these patient-derived HNSCC cell lines had been subjected to gene delivery, we used HeLa cells 
to test the RNAi protocol. At 48 h and 72 h post siRNA transfection, HeLa cells were directly 
subjected to RNA extraction for the detection of Mcl-1 alternative splicing pattern using RT-
PCR. As shown in Figure 2-29, SF3B1-siRNA delivery remarkably switched the dominant Mcl-
1 variant from Mcl-1L to Mcl-1S, indicating SF3B1 is involved in the alternative splicing of Mcl-
1 in HeLa cells. This initial observation, in consistent with the literature, indicated the efficiency 
of the transfection system.123 
 
Figure 2-29 SF3B1 knockdown switches the pattern of Mcl-1 alternative splicing 
 
Then, we knocked down SF3B1 in HPV16-positive UM-SCC47 and 93-VU-147T cell 
lines. These two cell lines bear distinct splicing patterns of E6; UM-SCC47 expresses 
comparable levels of E6 and E6* while 93-VU-147T cells mainly express E6 (Figure 2-28). In 
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all cases, cells were collected at 48 h post transfection because Mcl-1 was regulated similarly at 
48 h and 72 h of SF3B1 knockdown in HeLa cells (Figure 2-29). In addition, the deletion of 
SF3B1 caused significant cell death at 48 h post transfection, indicating an effective SF3B1 
knockdown. Figure 2-30 shows that SF3B1-siRNA effectively eliminated a majority of SF3B1 
protein in both cell lines. 
 
Figure 2-30 SF3B1 knockdown in UM-SCC47 and 93-VU-147T 
 
Figure 2-31 displays the effect of SF3B1 knockdown and meayamycin B, as single 
treatment or in combination, on the splicing of E6 and Mcl-1. RT-PCR was used to examine the 
relative abundance of each splice variant of E6 and Mcl-1. Without SF3B1 deletion, the E6/E6* 
ratios were 47/53 and 92/8 in UM-SCC47 and 93-VU-147T, respectively. In UM-SCC47, SF3B1 
knockdown increased the E6/E6* ratio to 82/18, while non-targeting siRNAs did not alter the 
ratio. The difference between the two treatments was less evident in 93-VU-147T, probably 
because of the low basal level of E6*. Analogous to the E6 system, the Mcl-1L/ Mcl-1S ratios in 
UM-SCC47 and 93-VU-147T cell lines were decreased by SF3B1 knockdown from 86/14 and 
81/19 to 65/35 and 48/52, respectively. These data indicate that SF3B1 is involved in the 
regulation of the splicing of HPV16 E6 and Mcl-1 in HNSCC cells.  
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Figure 2-31 SF3B1 controls splicing patterns of HPV16 E6 and Mcl-1 
 
Single-agent meayamycin B caused the splicing alterations to the E6 and Mcl-1 in 
HPV16-positive HNSCC cells. Hence we asked whether such effect from meayamycin B (Figure 
2-22 and 2-28) was solely via SF3B1 inhibition. We exposed UM-SCC47 and 93-VU-147T cells 
treated with SF3B1 siRNA or non-targeting siRNAs to 1 nM meayamycin B for 3 h. 
Interestingly, although meayamycin B-exposure alone altered the splicing patterns of E6 and 
Mcl-1, this combination treatment significantly enhanced the levels of changes caused by SF3B1 
knockdown (Figure 2-31). This was especially prominent in UM-SCC47 cells, with the E6/E6* 
ratios increased from 82/18 to 90/10, and Mcl-1L/ Mcl-1S ratios increased from 65/35 to 23/77. 
The fact that short-term, low-dose meayamycin B-exposure could change the splicing pattern 
beyond knocking down SF3B1 indicates other unknown mechanisms of meayamycin B exist, 
besides SF3B1-inhibition. In addition, effective siRNA knockdown requires 24–48 h depending 
on the targets, while small-molecule inhibitors quickly hits the proteins. Furthermore, for protein 
targets such as SF3B1 that extensively interact with RNAs and proteins, the differential effects 
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of siRNA knockdown and small-molecule inhibitors must be considered when examining the 
results. An siRNA eliminates the entire entity of the target, which in turn abrupt any interactions 
the target participates in. In contract, a small-molecule inhibitor might inhibit a subset of the 
functions of the target with minimum disturbance to the protein scaffold crucial for RNA-protein 
and protein-protein interactions.166 
2.3.3 Discussion 
More than 90% of human genes undergo alternative splicing to generate multiple mRNA 
variants in a tissue-specific manner.17 The corresponding protein isoforms have different, even 
antagonistic, properties. Their deregulation has been implicated in various disease states, 
including cancer.18 Therefore, alternative splicing represents a promising molecular therapeutic 
target. This study in seven HNSCC cell lines revealed that meayamycin B synergized with ABT-
737 to quickly trigger Bax/Bak-mediated apoptosis. Meayamycin B regulated alternative splicing 
of Mcl-1, increasing proapoptotic Mcl-1S and decreasing antiapoptotic Mcl-1L. The data from 
certain cell lines also indicated meayamycin B also inhibited constitutive splicing of Mcl-1 and 
E6, with partially spliced Mcl-1 leaked into cytoplasm. Interestingly, meayamycin B treatment 
can further enhance the extent of splicing regulation of E6 and Mcl-1 caused by SF3B1 
knockdown, demonstrating the existence of other splicing regulatory mechanisms by 
meayamycin B.  
The regulation of E6 splicing awaits full characterization. U1-binding cis-acting elements 
have been identified in the HPV16 genome.205 Our data demonstrate that U2 snRNP binds to 
HPV16 genome as well, possibly mediated by subcomplex SF3b. In addition, viruses can modify 
the expression of splicing factors in the host cells to meet their needs,206 calling for further 
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studies on the splicing regulations of these tumorigenic viruses in host cells. Distinct responses 
of HNSCC cell lines against meayamycin B also support the emerging needs to treat HPV16-
positive and HPV16-negative HNSCC as two separate diseases.  
In HNSCC, SF3B1 inhibitor meayamycin B and SF3B1 knockdown each could switch 
the splicing of HPV16 E6 and Mcl-1 towards E6 and Mcl-1S, respectively. These demonstrated 
that the biogenesis of E6* and Mcl-1S requires SF3B1 in HNSCC cells. Interestingly, 3-h 
treatment of meayamycin B significantly enhanced the effect of SF3B1 knockdown. Concerning 
the short-term effect of meayamycin B exposure, the enhancement of splicing regulation likely 
resulted from a direct interaction between meayamycin B and its binding targets. Possible 
explanations include the following: (1) meayamycin B might fit into an interface where SF3B1 
interact with its binding partners including SF3B3;100 (2) meayamycin B has other unknown, 
independent binding targets. This should not be surprising since FR901464 was suggested to 
target transmembrane thioredoxin-related protein.99  
In general, HPV16-positive cells showed higher resistance to meayamycin B or ABT-
737. This resistance was completely overcome when the compounds were combined. The 
resistance might stem from the oncogenic HPV16 proteins such as E6, E7 and E2 that negatively 
regulate the pro-apoptotic proteins in the host cells,188, 207-208 although this needs to be carefully 
examined in our experimental context.  
In four out of seven HNSCC cell lines, partially spliced, but not full-length unspliced, 
Mcl-1 pre-mRNA detected in RT-PCR using cytoplasmic RNA extracts. Mammalian cells 
possess stringent RNA surveillance system, with non-sense-mediated RNA decay (NMD) as the 
main pathway. NMD prohibits the export and translation of such misprocessed RNA species. It 
remains unknown why these partially spliced pre-mRNAs were only detected in certain cell 
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lines. Since pre-mRNA alternative splicing and NMD pathway are closely coordinated,104 it 
would be interesting to investigate how SF3b inhibitors might impact the NMD machinery-
mediated RNA surveillance at a global scope.  
A myriad of strategies employ genetic and pharmacologic approaches for targeting Mcl-
1.209 Since Mcl-1 is alternatively spliced into isoforms with antagonistic functions, targeting 
alternative splicing is advantageous; with the obliteration of antiapoptotic Mcl-1L, proapoptotic 
Mcl-1S increases and selectively neutralizes existing Mcl-1L. Here we report the first small 
molecule that modulates the splicing of Mcl-1 in HNSCC. Combined with our previous report in 
NSCLC, these studies demonstrate a positive correlation between the Mcl-1 level and the 
efficacy of SF3b inhibitors, highlighting their potential usage for cancers overexpressing Mcl-1. 
Meayamycin B and other FR901464 analogs presumably target SF3B1, which was 
recently reported to regulate Bcl-x alternative splicing in response to ceramide signaling.64 
Interestingly, Bcl-x, also abundantly expressed in HNSCC, was not altered by meayamycin B. 
This was consistent with our previous finding in NSCLC and Webb’s finding in pediatric 
rhabdomyosarcoma Rh18 cells.81, 195 The lack of changes in the Bcl-x system implies that SF3B1 
might be a splicing factor for Bcl-x that is exclusively involved in the ceramide-mediated spicing 
regulation. Importantly, the unresponsiveness of Bcl-x with extended exposure (48-h data not 
shown) indicates that the rapid modulation of Mcl-1 splicing was the main contributor to the 
rapid apoptosis we observed from the meayamycin B and ABT-737 combination. 
2.3.4 Conclusion 
In summary, we demonstrated that the combination of SF3B1 inhibitor meayamycin B and Bcl-
x/Bcl-2 inhibitor ABT-737 triggered apoptosis in HNSCC cell lines. Single-agent meayamycin B 
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elicited stronger toxicity in Mcl-1-abundant than in Mcl-1-deficient HNSCC, representing a 
potential therapy for Mcl-1-addicted cancer. In addition, we showed that HPV E6 as the first 
viral gene known to be regulated by SF3b inhibitors at the splicing level.  
2.3.5 Experimental 
Cell lines. Four HPV16-positive HNSCC cell lines, UD-SSC2 (gift from Professor Henning 
Bier, University of Dusseldorf, Germany),210 UM-SCC47 (gift from Professor Thomas Carey, 
University of Michigan),211-212 93-VU-147T (gift from Professor Hans Joenje, VU Medical 
Center, The Netherlands),213 UPCI:SCC90,214 and the HPV16-negative HNSCC cell lines PCI-
13 and PCI-15B (gifts from Professor Theresa Whiteside, University of Pittsburgh Cancer 
Institute)215 and UM-SCC22B (gift from Professor Thomas Carey, University of Michigan)216 
were used throughout the study. Bax-/-/Bak-/- and wild-type mouse embryonic fibroblasts (MEFs) 
were gifts from the late Professor Korsmeyer (Harvard Medical School) through Professor Scott 
Oakes (University of California, San Francisco).217 93-VU-147T cell line was cultured in 
Dulbecco's Modified Eagle's Medium /F12 medium (Gibco, New York), and other cell lines 
were cultured in DMEM (Gibco, New York). All cell culture media were supplemented with 
10% fetal bovine serum, 1% penicillin/ streptomycin, and 2% L-glutamine. Cells were 
maintained at 37 °C in air containing 5% CO2. 
Pharmacodynamic interaction analysis. The cells were exposed to meayamycin B and 
ABT-737 at various concentrations, either as single agents or in concomitant combinations (at a 
constant 3:5000 ratio) for 72 h until cell viability was monitored using the MTS (([3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner 
salt])) method. Bliss expected effect (EEXP, expressed as cell viability) from the combination of 
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meayamycin B and ABT-737 were calculated using EEXP=EA+EB-EA*EB, where EA and EB are 
effects from each single-agent treatment at a given dose. The difference between the Bliss 
expected and the observed effect (EOBS) of the combination is ΔE = EEXP – EOBS. ΔE scores were 
summed across the dose range to generate a Bliss sum. Bliss sum = 0 indicates that the 
combination treatment is additive (as expected for independent pathway effects); Bliss sum > 0 
indicates an activity greater than additive (synergy); and Bliss sum < 0 indicates the combination 
is less than additive (antagonism). 
Annexin V - fluorescein isothiocyanate (FITC) and propidium iodide (PI) staining. 
In all cases, cells were treated with 3 nM meayamycin B and 5 µM ABT-737 (alone or in 
combination), an equal volume of DMSO as a negative control, or 133 µM cisplatin as a positive 
control. Cells were treated for 5 h and stained with Annexin V-FITC (BD Pharmingen, CA) and 
PI (BD Pharmingen, CA) following the manufacturer’s protocol. The cells were then analyzed 
by flow cytometry using a CyAn cytometer (Beckman Coulter, CA). Data were analyzed using 
Summit V4.3 software.  
Caspase 3/7 activity assays. The cells, seeded at 1.0 x 104 per well in triplicate in white 
solid-bottom 96-well plates, were treated with 3 nM meayamycin B and 5 µM ABT-737 (alone 
or in combination) or an equal volume of DMSO as a negative control for 9 h. Then, caspase 3/7 
activity was monitored using Caspase-Glo® 3/7 reagent (Promega, WI) with a Modulus II 
Microplate Reader (Promega, WI) following the manufacturers’ protocols. The caspase 3/7 
activity was expressed as the mean luminescence signal from the compound-treated wells 
divided by that from vehicle-treated wells.  
RNA isolation and RT-PCR. Total RNA was isolated using RNeasy mini kit (QIAGEN, 
Maryland) and subjected to RT-PCR analysis (1 µg per reaction) using the SuperScript® II 
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reverse transcriptase (Invitrogen, New York). The thermocycler program for the HPV-16 E6 and 
E7, Bcl-x, Mcl-1, and β-actin involved an initial denaturation at 94 °C for 5 min, 30 cycles at 94 
°C for 30 sec, 58 °C for 30 sec, 72 °C for 50 sec, and a final elongation at 72 °C for 7 min. The 
primer sequences are included in Table 2-3. The PCR products were examined on 1.5% agarose 
gels and imaged by a Molecular Imager Gel Doc XR+ (Bio-Rad, CA). For each gel, the 
relative intensity of the bands was quantified with the Lab Imager software (Bio-Rad, CA). 
siRNA transfection. The pre-designed ON-TARGETplus modified siRNA duplexes 
targeting SF3B1 (020061-13) was obtained from Dharmacon (Dharmacon, MA). HeLa, UM-
SCC47 and 93-VU-147T cells were seeded (2.5 × 105) into 35-mm dishes and transfected with 
100 nM siRNA using lipofectamine 2000 (Invitrogen, NY) for 48 h before usage. siGENOME 
Non-Targeting siRNA Pool #2 (Dharmacon, MA) was used as a negative control. Transfection 
efficiency was evaluated by RT-PCR amplification of the HPV-16 E6, Mcl-1, and β-actin genes 
as described above. 
Western blotting. Cells were harvested in a cell lysis buffer (50 mM Tris-HCl, 150 mM 
NaCl, 1% Triton X-100, 0.1% SDS, and 1 mM PhCH2SO2F) and a cocktail of protease inhibitors 
(Roche, IN). Total protein (50 µg) was electrophoresed on a 12% SDS-polyacrylamide gel and 
transferred to polyvinylidene difluoride membranes (Millipore, MA). Membranes were blocked 
at room temperature for 1 h with a blocking buffer (5% non-fat dry milk in 10 mM Tris-HCl pH 
7.6, 150 mM NaCl, 0.1% Tween-20) and then incubated at 4 °C overnight with anti-SF3B1 
(D221-3, MBL), anti-Mcl-1 (5453S), anti-Bcl-2 (2870S), anti-β-actin (4970S) (Cell signaling 
technology, MA), or anti-Bcl-xL/Bcl-xS (sc-634) (Santa Cruz, CA) followed by 1-h incubation 
with a horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (7074S) (Cell signaling 
technology, MA) secondary antibody. Blots were developed with ECL Plus reagents 
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(PerkinElmer Life and Analytical Science, MA) and quantified using an Image Gauge Version 
4.0 (FUJIFILM, NJ). 
Statistics. Data analysis and graph plotting were carried out using a GraphPad Prism 5.0c 
for Mac (GraphPad Software). All of the data were presented as mean ± standard deviation and 
were analyzed by Student’s t test or ANOVA followed by the Tukey’s multiple comparison; the 
significance level for all analyses was 5%. 
 
Table 2-3 Primer sequences for RT-PCR experiments in HNSCC system 
Genes Sequences 
Bcl-x 
Bcl-xF: 5’- GAG GCA GGC GAC GAG TTT GAA -3’ 
Bcl-xR: 5’- TGG GAG TTG AGA GTG GAT GGT -3’ 
 
Mcl-1 
Mcl-1F: 5’- ATC TCT CGG TAC CTT CGG GAG C -3’ 
Mcl-1R: 5’- CCT GAT GCC ACC TTC TAG GTC C -3’ 
Mcl-2F: 5’- ATG TTT GGC CTC AAA AGA AAC GCG -3’ 
Mcl-2R: 5’- GGC TAT CTT ATT AGA TAT GCC AA-3’ 
HPV16 E6 
Forward: 5’- ATG CAC CAA AAG AGA ACT GC -3’ 
Reverse: 5’- TTA CAG CTG GGT TTC TCT AC -3’ 
HPV16 E7 
Forward: 5’- GTA ACC TTT TGT TGC AAG TGT GAC T -3’ 
Reverse: 5’- TTA TGG TTT CTG AGA ACA GAT GG -3’ 
β-actin 
Forward: 5’- GCA CCA CAC CTT CTA CAT GAG C -3’ 
Reverse: 5’- TAG CAC AGC CTG GAT AGC AAC G -3’ 
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2.4 MEAYAMYCIN B IN OTHER IN VITRO CELL MODELS 
2.4.1 Cisplatin-resistant ovarian cancer cells 
cis-diamminedichloroplatinum (II) (cisplatin) is an effective drug in the treatment of a variety of 
human tumors, including ovarian carcinoma. Unfortunately, a development of resistance is a 
major obstacle to the success of platinum-based chemotherapy, with fewer than 25% of the 
women diagnosed with advanced ovarian cancer showing progression-free survival after 4 
years.218 The cellular mechanisms of cisplatin-resistance are multifactorial, hence a longstanding 
challenge to circumvent in anticancer therapy.219 
The remarkable potency of the combination of meayamycin B and Bcl-x/bcl-2 inhibitor 
has been verified in NSCLC and HNSCC in vitro models. However, it is unclear whether it can 
overcome acquired drug resistance, such as the notorious cisplatin-resistance in ovarian cancer. 
To answer this question, we planned to determine whether meayamycin B (Figure 2-9), as single 
agent or in combination with ABT-737 (Figure 2-9), could enhance the efficacy of cisplatin, or 
overcome acquired cisplatin-resistance, in ovarian cancer models.  
Cisplatin-resistant human ovarian carcinoma 2008C cell line was generated by repeated 
selection of the cisplatin-sensitive ovarian cancer cells 2008 with 1µM cisplatin.220 The resulted 
cells, named 2008C, exhibited 2.7-fold higher resistance to cisplatin compared with the parent 
cell line 2008. As shown in Figure 2-32A, single-agent cisplatin exhibited GI50 values at 1.0 µM 
and 3.1 µM in 2008 and 2008C, respectively, consistent with literature.220 Single-agent 
meayamycin B caused ~50% inhibition of cell growth in 2008, but was inactive in 2008C. When 
combined simultaneously, meayamycin B and cisplatin did not affect each other in either cell 
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lines. These data demonstrated that cisplatin-resistant ovarian cancer cells are likely also 
resistant to meayamycin B and SF3b inhibition might not overcome cisplatin resistance. 
Subsequently, we examined the interaction of meayamycin B and ABT-737 in these 
ovarian cancer cell lines. Concerning the multifactorial resistance mechanism and the specific 
activation of apoptosis pathway by the combination, we envisioned that 2008C cells would be 
less sensitive than 2008.219 Indeed, 2008C was invariably more resistant to all treatments than 
2008. Nonetheless, the combination could cause 100% cell death in 2008 and 2008C with GI50 
values at 0.077 µM and 0.94 µM, respectively (Figure 2-32B). Therefore, meayamycin B and 
ABT-737 combination could overcome cisplatin resistance, with minor compromise in the 
efficacy.  
 
Figure 2-32 Meayamycin B and ABT-737 combination overcomes cisplatin resistance 
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2.4.2 Cervical cancer model cell lines 
Besides in a subgroup of HNSCC, HPV DNA is detected in over 90% of cervical cancer world 
wide, ~60% and  ~15% of which are HPV16 and HPV18, respectively.221 In addition to this 
common molecular feature, cervical cancer and HNSCC share the risk factors that are common 
for sexually transmitted diseases.222 Hence, it would be interesting to examine the efficacy of 
meayamycin B, as single agent or in combination with ABT-737, in cervical tumor cell lines.  
To this end, we chose Caski and Siha, which have ~600 and 1–2 copies of genomically 
integrated HPV16 DNA, respectively.223 Figure 2-33A shows the caspase 3/7 activity in each 
cell line exposed to each single agent (10 nM meayamycin B or 5 µM ABT-737) or the 
combination, for 9 h or 24 h. Within 9 h, the combination significantly induced the activity of 
caspase 3/7, while single agents led to negligible to minor increase. Of note, by 24 h, the cells 
were almost completely eliminated in the combination-treated samples. The GI50 values for 72-h 
MTS assays indicated single agents or the combination was 2-fold more active in Caski than in 
Siha (Figure 2-33B). Although Caski harbors notably more copies of HPV16 than Siha, it is 
unknown how many of these copies are transcriptionally competent. Such differential responses 
to meayamycin B were also observed in HPV16 positive and HPV16 negative HNSCC cell lines. 
The functions of high-risk HPV oncogenic genes, especially those from HPV16, have been better 
understood in cervical cancer. Screening and characterizing more cervical cancer cell lines might 
provide us insights into the molecular mechanism underlying this differential meayamycin B-
sensitivity. 
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Figure 2-33 Antiproliferative and caspase 3/7 assays in cervical cancer cells 
2.4.3 Experimental 
Cell lines. Cisplatin sensitive 2008 and resistant 2008C cells are gifts from Dr. Van Houton 
(University of Pittsburgh Cancer Institute). Siha and Caski (gifts from Dr. Robert Ferris) were 
maintained in Dulbecco's Modified Eagle's Medium (Gibco, NY). Cells were maintained at 37 
°C in air containing 5% CO2. 
Caspase 3/7 activity assays. The cells, seeded at 1.0 x 104 per well in triplicate in white 
solid-bottom 96-well plates, were treated with 3 nM meayamycin B and 5 µM ABT-737 (alone 
or in combination) or an equal volume of DMSO as a negative control for 9 h and 24 h. Then, 
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caspase 3/7 activity was monitored using Caspase-Glo® 3/7 reagent (Promega, WI) with a 
Modulus II Microplate Reader (Promega, WI) following the manufacturers’ protocols. The 
caspase 3/7 activity was expressed as the mean luminescence signal from the compound-treated 
wells divided by that from vehicle-treated wells.  
Cell proliferation assay. Cell proliferation was evaluated using the MTS dye reduction 
assay with PMS as the electron acceptor assay performed in triplicate. To this end, cells were 
seeded in 96-well plates at 6×103 cells per well and incubated for 24 h at 37 °C. Cells were then 
exposed to various concentrations (serial three-fold dilutions) of the meayamycin B and ABT-
737 or cisplatin, as single agents or in 1:500 constant ratio, for 72 h at 37 °C. An MTS solution 
(20 µL of MTS: PMS at 20:1) was added, and cells were incubated for 2 h at 37 °C before the 
absorption signals were measured at 490 and 650 nm. Growth inhibition was calculated as 
defined by the National Cancer Institute [GI50 = 100 × (T-T0)/(C-T0); T0 = cell density at time 
zero; T = cell density of the test well after period of exposure to test compound; C = cell density 
of the vehicle treated]. 
Statistics. Data analysis and graph plotting were carried out using a GraphPad Prism 5.0c 
for Mac (GraphPad Software). All of the data were presented as mean ± standard deviation and 
were analyzed by Student’s t test or ANOVA followed by the Tukey’s multiple comparison; the 
significance level for all analyses was 5%. 
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3.0  ACTIVATION OF SV40 PROMOTER AND INHIBITION OF LUCIFERASE BY 
TMC-205 AND ANALOGS 
This section is in part taken from the manuscript “Gao, Y., Osman, S., and Koide, K. Total 
synthesis and biological studies of TMC-205 and analogs as anticancer agents and activators of 
SV40 promoter”, submited to ACS Med. Chem. Lett. 
3.1 RESEARCH PLAN 
TMC-205, an indole derivative isolated from an unidentified fungal strain TC 1630. The natural 
product was cytotoxic against various human cancer cell lines with GI50 values in the range of 
52–203 µM.224 TMC-205 showed light- and air- sensitivity, preventing thorough exploitation of 
its potential as cancer therapeutics. Being isolated as a transcription activator, TMC-205 
activated the expression of Simian virus 40 (SV40) promoter via an unknown mechanism. Other 
natural products discovered by this route include azelaic bishydroxamic acid,225 trichostatin A,226 
FR901228,227 herboxidiene87, 121 and FR901464.82-84 Mechanistic studies using these small 
molecules demonstrated that inhibitions of histone deacetylases and spliceosome are viable 
cancer therapeutic approaches.100, 228-232  
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To fully exploit the potential of TMC-205 as an antiproliferative agent against cancer, 
herein we performed the synthesis of TMC-205 and its light- and air-stable analogs, which were 
subsequently applied in biological activity evaluations. Two activities examined include SV40 
promoter-activation and direct luciferase binding.233-236     
TMC-205 experiences photosensitized singlet oxygen-mediated degradation. Its trifluoro-
substituted stable analogue maintains the activity to inhibit cell growth and activate SV40 
promoter-driven luciferase expression, and also inhibit firefly luciferase. These data prime for 
further development of these novel anticancer agents with multifactorial mode of action. 
3.2 RESULTS AND DISCUSSION 
This project was completed in collaboration with Dr. Sami Osman, who accomplished the 
synthesis of TMC-205 and its analogs. The anti-proliferative activities of these compounds were 
obtained in HCT-116 cell line (Table 3-1). He also discovered that TMC-205 selectively reacts 
with singlet oxygen, which affords its sensitivity to air and light under laboratory ambient 
conditions. 
The biological studies presented herein were mainly carried out using TMC-205 and its 
stable analogs including 12 and 14 that are 2–8 fold more potent than TMC-205 against HCT-
116 (Table 3-1). 
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Table 3-1 Antiproliferative activity of TMC-205 and its analogs against HCT-116 
 
3.2.1 Viral promoter activation 
Previously, TMC-205 was found to activate a luciferase gene driven by an SV40 promoter in an 
SV40 enhancer-dependent manner using the pGL3-control (Promega).224 The activation of the 
luciferase gene driven by the SV40 promoter without the SV40 enhancer (pGL3-promoter, 
Promega) was negligible in the presence of TMC-205 (Figure 3-1).  
N
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Figure 3-1 SV40 enhancer-dependent activation of SV40 promoter  
 
With 24-h exposure, TMC-205 and 12 activated SV40 promoter in the presence of 
enhancer in HeLa cells stably transfected with pGL3-control (Figure 3-2A and B). Interestingly, 
in our hands, pGL3-promoter could be activated by TMC-205 as well (Figure 3-2C, transient 
transfection) – meaning the gene activation was independent of SV40 enhancer.  
 
Figure 3-2 TMC-205 activates SV40 promoter independent of enhancer 
 
Analogs 12 and 14 also activated the expression of SV40:luciferase without inhibiting 
cell growth (Figure 3-3A and B). It is noteworthy that within the 24-h time frame before cell 
growth can be influenced, analogue 12 activated gene transcription in a nanomolar range (Figure 
3-2B); such a property is critical for gain-of-function techniques used in live cell models. 
Luciferase
LuciferasePSV40
PSV40 ESV40
TMC-205
pGL3-control
pGL3-promoter
TMC-205
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Previously, it was discovered that singlet oxygen reacts with TMC-205. Therefore, resveratrol 
was also examined for SV40 promoter activation because of its selective reactivity to singlet 
oxygen. Interestingly, resveratrol also activated SV40 promoter in pGL3-promoter in a dose-
dependent manner (Figure 3-3C). 
 
Figure 3-3 Compounds 12, 14 and resveratrol activate SV40 promoter 
3.2.2 Luciferase inhibition 
Firefly luciferase is the reporter enzyme in the vectors used both in the original isolation study 
and our current SAR studies for TMC-205 and its analogs. Recently, it was discovered that 
luciferase catalyzed luminescence-emission is prone to perturbation by certain heterocyclic small 
molecules either through luciferase binding or compound-specific luminescence absorbance or 
scattering.233-234 In the case of direct binding, these small molecules inhibit luciferase, 
competitively or non-competitively with D-luciferin and/or ATP. Concerns arise when the tested 
compounds that are active against luciferase might also be active against a target of interest. For 
example, high throughput screenings for enzymes, such as kinases that are also ATP-dependent, 
would inevitably be susceptible to luciferase inhibitory activity of the hits.237-238 For the current 
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study, direct attenuation of luminescence was not a concern for two reasons: first, as shown in 
Figure 3-4, analogue 12 absorbs UV light with a peak at 290 nm, with no absorption in the range 
of visible light (400–700 nm); second, compound-containing cell medium was thoroughly 
removed for the luciferase reporter assay.  
 
Figure 3-4 Absorption spectra of compound 12 
 
We decided to examine the interaction between recombinant luciferase and analogue 12. 
Resveratrol was applied in parallel as a positive control since it was confirmed to be a non-
competitive luciferase inhibitor.239 Substrate competition assays were carried out by varying 
concentrations of ATP or D-luciferin to acquire the dose-response curves of luciferase inhibition 
by 12 and resveratrol. If a test compound antagonizes either of the native ligands, increasing the 
concentration of this ligand would abolish the inhibition caused by the test compound. As shown 
in Figure 3-5, varying ATP concentration did not significantly change the IC50 values of 12 or 
resveratrol, which implies that 12 or resveratrol does not antagonize ATP.240 D-luciferin, on the 
other hand, perturbed the inhibitory capability of 12 in a dose-dependent manner, indicating that 
12 might share the same binding pocket with D-luciferin.   
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Figure 3-5 Compound 12 and resveratrol non-competitively inhibit luciferase 
 
Based on these data, we speculated that the strong luciferase inhibition would result in an 
underestimate of expression activation of luciferase by 12. We set out to examine the expression 
of luciferase at the mRNA level. To this end, the total RNA extracted from 12-, resveratrol-, 
meayamycin-, and DMSO-treated HeLa cells expressing pGL3-promoter was analyzed by RT-
PCR for luciferase level (Figure 3-6). Meayamycin was included as a positive control for SV40 
promoter activation. In a dose-dependent manner, 12, resveratrol (RSV), and meayamycin 
(MAM) exhibited moderate activation of the SV40 promoter. This data demonstrated that 12 and 
resveratrol share the common activities of luciferase inhibition and SV40 promoter activation, 
while meayamycin only activates SV40 promoter.  
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Figure 3-6 Activation of Luciferase expression at the mRNA level 
3.3 CONCLUSION 
In conclusion, TMC-205 and its stable analogs 12 and 14 activated SV40 promoter in an 
enhancer-independent manner. Through biochemical assays and RT-PCR, we proved that 12 also 
exhibited nanomolar binding-affinity for firefly luciferase.  
3.4 EXPERIMENTAL 
Cells, reagents and plasmids. HeLa cells are gifts from Professors Andreas Vogt and Billy Day 
(University of Pittsburgh), respectively. HeLa cells were maintained at 37 °C in an atmosphere 
containing 5% carbon dioxide in Corning cell culture dishes (150 mm) in RPMI cell culture 
medium containing 10% fetal bovine serum, 1% L-glutamine, and 1% penicillin-streptomycin 
 100 
solution (Invitrogen). pGL3-control and pGL3-promoter vectors were purchased from Promega 
(cat# E1741, E1761). GenCarrier-1 was purchased Epoch Biolabs. All synthetic compounds 
were dissolved in DMSO as stock solutions and stored at -20 °C. For the experiments, aliquots 
were thawed at room temperature in a dark environment, and diluted solutions were prepared in 
cell culture medium containing 1% DMSO prior to addition to the cell culture media. 
Luciferase reporter assay with TMC-205 and its analogs. All compounds were diluted 
to 10 mM stock solutions and stored at -20 °C. Diluted solutions in DMSO were prepared 
immediately before use and administered directly into cell cultures. The final DMSO 
concentration was 0.5% (v/v), which was demonstrated to be nontoxic for cells. For transfection, 
HeLa cells were seeded in 35-mm tissue culture dishes in RPMI medium and allowed to reach 
70% confluency upon transfection.  
For transient transfection, cells were transfected with a pGL3-control or a pGL3-
promoter vector and GenCarrier-1 in serum-free medium containing vector and GenCarrier-1 (1 
µg and 2 µL per dish). After 48 h of transfection, cells were trypsinized and seeded at a density 
of approximately 15,000 cells per well in a 96-well plate in RPMI medium (200 µL), and 
allowed to attach overnight. The cells were then treated with synthetic TMC-205 at the indicated 
concentrations for 24 h. The cell culture medium was then removed, and cells were rinsed once 
with phosphate-buffered saline (PBS) before 1 × cell lysis buffer (20 µL) was added to each 
well. After homogenization for 10 min at room temperature, cell lysates were subjected to 
luciferase assay reagent (100 µL; Promega) and luminescence was measured immediately on a 
Spectromax M5 plate reader (Molecular Devices) or Modulus II Microplate Multimode Reader 
(Turner BioSystems). With the M5 plate reader, white 96-well plates with clear bottom were 
used. With the Modulus II, white solid-bottomed 96-well plates were used. 
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For stable transfection, HeLa cells were transfected with a 9:1 w/w pGL3-control or 
pGL3-promoter and pREP4. Stable transfectants selection, in a medium containing 250 µg/mL 
of hygromycin B, started 48 h post transfection in the same dish where transfection took place. 
After 2 weeks of continuous selection, hygromycin B-resistant cells formed colonies, each of 
which consisted of hundreds of cells. These single cell colonies were amplified and maintained 
for five passages and assayed for luciferase expression and response to the activation of the 
SV40 promoter. Thereafter, luciferase-expressing colonies that most strongly responded to the 
promoter activation were reserved and maintained for another 15 generations prior to being used. 
Approximately 10,000 cells were seeded in each well of a 96-well plate in an RPMI medium 
(200 µL) and were allowed to attach overnight. The cells were treated with the compounds at the 
indicated concentrations for 24 h before luciferase assay analysis was undertaken as mentioned 
above. 
Firefly luciferase inhibition assay. To determine whether ketone 12 competes with ATP 
or D-luciferin (i.e. competitively inhibits luciferase by direct binding), dose-dependence studies 
for ketone 12 were carried out with varying concentrations of ATP or D-luciferin for 
recombinant firefly luciferase (Promega) activity assays. Each assay reaction was performed in 
white solid-bottom 96 well plates. To each well, the following reagents were added sequentially: 
ketone 12 or resveratrol (2 µL of stock solution at appropriate concentration), 181 µL luciferase 
assay buffer (pH 7.5 Tris acetate 50 mM, MgSO4 10 mM, pH 8.0 EDTA 2 mM, sodium 
pyrophosphate 1 µM, DTT 5 mM, and ATP at various concentrations, see below) and 
recombinant luciferase (1 µL at 1 mg/mL). Then the mixture was incubated at room temperature 
for 5 min before 16 µL D-luciferin (at appropriate concentration dissolved in MiliQ H2O) was 
added. To study the competition between ATP and ketone 12, the final concentration of D-
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luciferin was controlled at 0.4 mM, and various amounts of ATP (0.04–5 mM) were included in 
the assay buffer. To study the competition between D-luciferin and ketone 12, ATP was 
controlled at 1 mM and various amounts of D-luciferin (0.001–1 mM) were added to the assay. 
For each study, resveratrol (10 mM in DMSO) or ketone 12 (20 mM in DMSO) were diluted in 
DMSO and directly added to the reaction mixtures. Each treatment was performed in duplicate. 
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